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ABSTRACT
MARKERS AND MECHANISMS OF METABOLIC AGING
Peter D. Ahiawodzi
April 17, 2014
Oxidative stress has been implicated in aging and age-related diseases. Using
three distinct studies, this dissertation examines associations between lifestyle factors and
oxidative stress, and their effects on advanced glycation end products, telomere length,
and type II diabetes.
Carboxymethyl-lysine (CML), an advanced glycation end-product, has been
linked to oxidative stress, cardiovascular and other age-related diseases. The first study
investigates the association between sleep disordered breathing (SDB), a source of
oxidative stress, and CML. 1002 participants with sleep data from the Cardiovascular
Health Study (CHS) were analyzed. SDB was not significantly associated with CML, but
after stratification by gender and hemoglobin it was found that among female subjects
with higher hemoglobin levels, those with more severe SDB had a significantly higher
CML concentration, while the reverse was observed among males.
Telomere length is another biomarker of cumulative exposure to oxidative stress
and an indicator of aging. In the second study, 974 participants from the Framingham
v

Heart Study were analyzed to investigate the role of modifiable factors known to affect
oxidative stress including obesity, cigarette smoking, excessive alcohol consumption, and
physical inactivity, on telomere length. Age, gender, BMI, and alcohol consumption were
found to significantly influence telomere length.
Diabetes and its complications have roots in oxidative stress. Sleep disturbance,
especially sleep apnea, is a potential source of oxidative stress. A total of 9635
participants in the first National Health and Nutrition Examination Survey were followed
from 1982 to 1992. Time to diabetes was modeled as a function of sleep quality and
quantity with adjustment for potential confounders. Sleep quality, but not sleep quantity,
was significantly associated with type II diabetes.
In conclusion, oxidative stress plays a vital role in aging and age-related diseases.
This dissertation emphasizes the importance of good sleep hygiene, healthy weight, and
moderate alcohol consumption to curb the burden of oxidative stress on the human
system. These findings may be considered in the policy framework of interventions
aimed at reducing age-related diseases, to promote healthier aging and longevity.
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CHAPTER ONE
BACKGROUND
1.1 Evolutionary Theories of Aging
Aging is a major contributor to Alzheimer’s disease, atherosclerosis, osteoporosis
and autoimmune diseases1. Why and how organisms age is still not fully understood.
Weismann et al.,2 proposed that aging is a death-mechanism, an adaptive response to
exclude old members of population on a schedule responsive to new propagation,
primarily under selection against overcrowding. Another school of thought suggests that
late-acting deleterious effects of accumulated mutations in the cells of organisms
contribute to aging of the organism. This is known as the somatic mutational theory and
was proposed by Smith in 1962 when he used ionizing radiation to argue that radiation
causes genetic mutations and shortens lifespan, and could serve as a major force in
aging3.
More recently, disposable soma theory was proposed to explain variation among
species in characteristic lifespan. The theory considers lifespan a trait evolved by
selection primarily on the energetic requirements of complex organisms. Under the
theory, the somatic self of an organism is a system of high energy demand for both
reproductive and non-reproductive activities. From birth to death the molecular processes
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of DNA replication and repair, protein synthesis and replenishment, require considerable
energy expenditure, and lifespan is viewed as an average balance in tradeoffs between
energy costs and investments that sustain the somatic and behavioral functions of an
organism, at least through reproduction. Post-reproductively selection pressure falls off,
and with the passage of time, the energetic maintenance of these basic systems declines
causing systemic defects to accumulate and manifest as aging, or senescence of the
organism4-6.

1.2 The Free Radical Theory of Aging
The free radical theory of aging was first proposed by Harman in 1956 and states
that lifespan is mainly dependent on the production of intracellular reactive oxygen
species (ROS)7. This theory is based on the premise that the harmful effects of ROS on
various cells and organs results in their functional deterioration, and are often expressed
as general decline and/or diseases associated with advancing age. The theory was
expanded later to identify mitochondrial production of O2•- and H2O2 as the main source
of ROS production causing age-related damage and organ dysfunction8.

1.3 Mitochondrial DNA and Reactive Oxygen Species
Mitochondria are present by the hundreds in every human cell, and each
mitochondrion contains multiple small circular genomes (mtDNA). Mitochondria are the
sites within cells of energy production and transport, where food and oxygen intake
generate chemical energy and heat for work and maintenance of body temperature. This
process of oxidative phosphorylation (OXPHOS) to produce energy (ATP) occurs by
oxidizing hydrogen from consumed carbohydrates and fats in an ordered sequence of
2

electron transport: electrons from NADH+H+ or from succinate are donated to NADH or
succinate dehydrogenase, then passed to coenzyme Q (CoQ) to produce ubisemiquinone
(CoQH•), then ubiquinol (CoQH2), and to cytochrome c oxidoreductase (complex III).
Electrons are then transferred from complex III to IV, also known as cytochrome oxidase,
where 1/2O2 is produced and finally H2O. It is the flow of electrons through this transport
chain (ETC) that releases energy which in turn pumps protons out of the inner membrane
of the mitochondria creating an electrochemical gradient which also captures energy to
aid ATP release. The mitochondria in turn generate (ROS) as by-products of the energy
production process: these include superoxide anion, hydrogen peroxide, and highly
reactive hydroxyl radical. These free radicals then inflict damage on the mitochondria,
mtDNAs, and the cell with downstream pathological consequences including
hypertension, atherosclerosis, and diabetes9-12.
Retention of electrons in the initial steps of the ETC generate ROS as by-products
when unpaired electrons at CoQ binding-sites of complexes I, II, and III are directly
donated to O2 to generate superoxide anion (O2•-), then converted to H2O2 in the presence
of Manganese superoxide dismutase (MnSOD). Finally, H2O2 converts to the highly
reactive hydroxyl radical (OH•) in the presence of iron or other transition metals9, 13, 14.
Retention of electrons in the ETC occurs when calories are consumed in excess of the
demand for their use, or with lack of exercise. Caloric intake without compensatory
exercise, ramps down ATP production, causes hyperpolarization of the electrochemical
gradient, and the eventual inhibition of OXPHOS, while leaving untransported electrons
as free radicals available for ROS production9.
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These reactive oxygen species could cause mitochondrial DNA mutations and
these defects in the mitochondria could lead to dysfunction and eventually death.
Mitochondrial production of reactive oxygen species is significantly increased in the
heart and increases cardiac aging. This is because the heart is an organ that is very rich in
mitochondria because of its high metabolic demand. Reactive oxygen species production
is therefore very high in the heart making the heart very susceptible to oxidative
damage15, 16. In support of the free radical theory of aging Schriner et al., compared mice
that overexpressed human catalase localized to the mitochondria with wild-type litter
mates. They found that cardiac malfunction was delayed, and H2O2 production and
mitochondrial DNA mutations were reduced, and lifespan increased in mice
overexpressing human catalase targeted to the mitochondria17. Mitochondrial reactive
oxygen species have also been linked to vascular aging by induction of apoptosis and
studies have shown that the rate of endothelial apoptosis was increased with oxidative
stress18, 19. Endothelium-dependent vasodilation has also been proposed to be the result of
mitochondrial oxidative stress and can cause a drop in blood pressure sufficient enough
to produce shock20, 21. Moreover, defects to the mitochondria as a result of reactive
oxygen species could collapse the blood-brain barrier and lead to neuroinflammation
associated with aging. This is because the integrity of the blood-brain barrier depends on
the proper functioning of the mitochondria and inhibition of the mitochondrial function
has adverse consequences for the blood-brain barrier22.

1.4 Other Sources of Reactive Oxygen Species
Mitochondria produce most of the endogenous reactive oxygen species23, 24.
However various enzymes localized elsewhere within the cell are also involved in ROS
4

production, including NADPH oxidase at the plasma membrane, lipid oxidation within
peroxisomes, and xanthine oxidase in the cytoplasm.
1.4.1 Reactive Oxygen Species Generation by NADPH Oxidase
The human immune system is comprised of phagocytes (neutrophils, monocytes,
eosinophils) that fight invading pathogens with the help of antimicrobial oxidants such as
O2•- and H2O2. NADPH oxidase is responsible for the generation of these antimicrobial
oxidants. NADPH oxidase is activated when cells come into contact with bacteria or
other inflammatory stimuli and catalyzes the reduction of oxygen to O2•- to kill bacteria25.
The superoxide anion can undergo further reactions to form the more potent hydroxyl
radical (OH•). This can happen in two ways: by the Fenton mechanism (Fe2+ + H2O2 →
Fe3+ + OH• + OH-) or the Haber–Weiss mechanism (O2•- + H2O2 → OH• + OH- + O2;
catalyzed by Fe3+)26. Release of these oxidants is essential for immune system function,
but excessive release can cause inflammatory tissue injury and eventual dysfunction of
the associated organs27.
1.4.2 Reactive Oxygen Species Generation by Xanthine Oxidase
The phenomenon of the “oxygen paradox” proposed that post-ischemic tissue
injury is mainly attributed to free radical production during reoxygenation28-30. In
ischemic states like myocardial infarction and stroke there is severe restriction of blood
flow to tissues and the immediate medical solution is to restore oxygen. However,
depending on the duration of the ischemia it has been found that tissue damage occurs as
a result of reoxygenation of the ischemic tissues. There are two processes that lead to free
radical production in post-ischemic tissues. Firstly, Ischemic conditions enable the
conversion of xanthine dehydrogenase to xanthine oxidase. Secondly, in ischemia there is
5

depletion of ATP to AMP. Catabolism of AMP eventually leads to accumulation of
hypoxanthine which is the substrate for the enzyme xanthine oxidase. Xanthine oxidase
then catalyzes the oxidation of hypoxanthine to xanthine and further catalyzes the
oxidation of xanthine to uric acid, and molecular oxygen (in reperfusion) to O2•- and
H2O2. Further reactions in the ischemic tissue promote the formation of OH• via the
Fenton mechanism. This increased free radical production in ischemic diseases such as
stroke and myocardial infarction has therefore been proposed as a major factor in
reperfusion-induced injury26, 31.
1.4.3 Reactive Oxygen Species Generation by Lipid Oxidation
Peroxisomes are membrane-bound organelles that are present in the cytoplasm of
all eukaryotic cells. They are involved in metabolism and contain enzymes that oxidize
fatty acids and amino acids. As part of the peroxisomal metabolism reactive oxygen
species are produced. Peroxisomal enzymes such as acyl-CoA oxidase, D-amino acid
oxidase, and xanthine oxidase produce H2O2 which can undergo the Fenton reaction to
produce the more potent hydroxyl radical32. Peroxisomes also contain the enzyme
catalase, the most abundant peroxisomal antioxidant enzyme, which decomposes H2O2 to
water, hence peroxisomes are protective against oxidative stress in the cell. Increased risk
of age-related diseases including diabetes, atherosclerosis, and cancer have been found in
individuals deficient in the enzyme catalase33. Oxidative stress occurs when the
production of reactive oxygen species in the peroxisome exceeds that which can be
adequately detoxified34, 35. The xanthine oxidase in the peroxisome can also reduce
nitrates and nitrites to NO•36. However NO• can react with O2•- to produce ONOO- which
is a strong oxidizing agent and capable of rendering peroxisomal enzymes inactive37.
6

This also leads to decrease in nitric oxide bioavailability. Nitric oxide is vasodilatory in
function and therefore has antiproliferative effect on smooth muscle cells. Depletion of
nitric oxides leads to vascular thickening and loss of elasticity and hence endothelial
dysfunction38.

1.5 Advanced Glycation End-Products
Advanced glycation end products (AGEs) are a heterogeneous group of
macromolecules that are formed by the nonenzymatic glycation of proteins, lipids, and
nucleic acids. AGE formation induces oxidative stress which indirectly causes more
AGEs production39, 40. AGEs have been implicated in pathologies such as diabetic
microvascular disease, connective tissue diseases (esp. rheumatoid arthritis), Alzheimer’s
disease, end-stage renal disease, hypertension, atherosclerosis and many other age-related
disorders39. Accumulation of AGEs occurs with age and as part of normal metabolic
processes. However, accelerated production is associated with diabetes due to
hyperglycemia and leads to vascular damage and eventual microvascular complications
such as neuropathy, nephropathy, and retinopathy39, 41. Carboxymethyl-lysine (CML), a
well characterized AGE, is formed on protein by combined nonenzymatic glycation and
oxidation reactions, and also during metal-catalyzed oxidation of polyunsaturated fatty
acids in the presence of protein (lipid peroxidation). CML is characterized as a general
biomarker of oxidative stress and damage in tissue proteins42.
1.5.1 Hypoxia, Lysyl Oxidase Activity, and Carboxymethyl-lysine
Collagen is the protein that forms connective fibers in tissues. Collagen fibers
keep bones and blood vessels strong. Collagen is also required for the repair of blood
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vessels. It is the main component of connective tissue, and is the most abundant protein
in mammals43. Elastin is a major component of the extracellular matrix. It is a protein in
connective tissue that is elastic and allows tissues in the arterial wall to resume their
shape after stretching or contracting. Degradation of elastin in arterial walls is a
characteristic feature of atherogenesis44. The biomechanical properties of the vessel wall
are determined largely by the extracellular matrix proteins collagen and elastin. The
degree of cross-linking is a critical feature of collagen and elastin fibers. The cross-links
in collagen contributes to the stiffness of collagen fibers45, whereas the cross-links in
elastin are important for the rubber-like properties of elastin fibers46.
Lysyl oxidase catalyzes the covalent cross-linking of collagen and elastin in the
extracellular space by oxidizing specific lysine residues in these proteins. The crosslinking of collagen and elastin stabilizes these proteins and also helps in the formation
and repair of the extracellular matrix. Thus lysyl oxidase activity is essential in
maintaining the tensile and elastic features of connective tissues of many systems
including the pulmonary system47. Downregulation of lysyl oxidase has been associated
with endothelial dysfunction48,

49

. However, overexpression of lysyl oxidase has been

associated with pulmonary arterial stiffness in hypertension50 , atrial fibrillation51, and in
tumor initiation and progression52.
It has been found that hypoxia increases lysyl oxidase gene expression levels 50,

53

.

Endothelial cells respond to hypoxia by remodeling the extracellular matrix. This implies
an upregulation of lysyl oxidase, a vital enzyme in extracellular matrix assembly.
Furthermore, it has been found that the hypoxia-induced increase in lysyl oxidase
expression is associated with increased levels of reactive oxygen species54.
8

These findings indicate that hypoxia in SDB disrupts lysyl oxidase activity. The
overexpression of lysyl oxidase in the extracellular matrix is also an indication of
increased lysine modifications including carboxymethyl-lysine (CML)55, 56.

1.6 Oxidative Stress and Disease
When an imbalance exist between prooxidant and antioxidants such that
prooxidant levels exceed that of antioxidants the situation is referred to as oxidative
stress. This can result from diminished antioxidant levels (vitamins E, C, and D,
flavonoids and carotenoids) and micro-nutrient levels (iron, copper, zinc, and selenium).
These micro-nutrients play vital roles in the proper functioning of antioxidant enzymes
(copper/zinc superoxide dismutase, catalase, or glutathione peroxidase). Depletion of
these nutrients and dysfunction of antioxidant enzymes leads to increased accumulation
of reactive oxygen species26 from any of the mechanisms described above. Since
proposed by Harman in 19567, 23 oxidative stress remains the most widely accepted cause
of aging and age-related diseases. Oxidative stress has been associated with aging in
humans, and diseases such as diabetes, Parkinson’s disease, Alzheimer’s disease,
amyotrophic lateral sclerosis, Huntington disease, cancer, and cardiovascular disease57-64.
Reactive oxygen species (O2•-, H2O2, and OH•) impose oxidative damage on
important proteins, lipids, nucleic acids65-67. The hydroxyl radical has the ability to
modify DNA bases and also cause strand breaks, leading DNA damage68. It can attach to
the C-8 position of guanine to form 8–hydroxyguanine (8-OH-guanine) which has been
implicated in Parkinson’s disease and Alzheimer’s disease69, 70. Another effect of
oxidative damage on DNA bases is mutation arising from AT↔GC transition and by
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GC↔TA transversion, which can result in changes in protein gene expression26. In
proteins, reactive oxygen species cause damage by forming protein modifications such as
carbonyls, dityrosine, and nitrated and chlorinated tyrosines, and these have been found
at elevated levels in inflammatory disease patients26. In the presence of reactive oxygen
species and oxygen, lipids undergo peroxidation in which several molecules of lipid (LH)
are oxidized. The process involves the highly reactive hydroxyl radical extracting the
allylic hydrogen from the lipid thereby forming a carbon-centered lipid radical (L•),
which reacts with oxygen to form a lipid peroxy radical (LOO•). Lipid peroxidation of
low-density lipoprotein (LDL) and subsequent accumulation of the oxidized LDL leads
to the formation of foam cells from macrophages, the initial stage of Atherosclerosis26, 71,
72

.

1.6.1 Oxidative Stress and Type-2-Diabetes
The β-cells of the pancreas produce insulin which is important in glucose
metabolism. It has been established that elevated levels of long chain saturated nonesterified fatty acids exhibit a strong cytotoxic effect on the β-cells resulting in β-cell
dysfunction and apoptosis73, 74. Metabolism of long chain non-esterified fatty acids in the
peroxisomes leads to the formation of H2O2 which is thought to mediate the lipotoxicity
of the β-cells75. The β-cells are particularly vulnerable to the toxic effects mediated by
H2O2 because β-cells lack catalase, the enzyme responsible for decomposing H2O2 to
water76, 77.
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1.6.2 Oxidative Stress and Leucocyte Telomere Length
As discussed earlier oxidative stress is associated with aging57. Telomeres have
also been found to play a major role in human aging, raising discussions on the
relationship between oxidative stress and telomere length78. Telomeres are repetitive
DNA sequences that cap the ends of chromosomes. In humans, the long stretches of the
tandem repeats are made up of TTAGGG79. Telomeres function to regulate the
proliferation of cells in organisms. This role was made possible because telomeres
shorten as the organism ages and this shortening place limits on the number of
replications that the cells of the organism can undergo. The decreased proliferative
potential of the cell due to telomere attrition may cause alterations in cellular metabolism
and lead to apoptosis78.
Genetic and environmental factors influence telomere length: these include
physical activity, tobacco smoking, socio-economic status, body-mass index, alcohol
consumption, multivitamin intake, dietary antioxidants, paternal age at time of
offspring’s birth, and perceived stress and adverse life events. These factors may increase
or decrease oxidative stress and inflammation, which are very important in telomere
length dynamics and aging80-88. Eisenberg78 proposed the “thrifty telomere model” which
states that regulation of maintenance effort in an organism is the main function of the
telomeres. This suggests that telomeres are responsible for programming the allocation of
resources within the organism. Hence factors like tobacco use, alcohol consumption, and
obesity, which potentially place extra oxidative burden on the cells of the organism could
lead to shorter telomeres because the extra oxidative burden could only be met when part
of the soma is lost (in this case, telomere length reduction). As telomeres become
11

shorter, the replicative capacity of the cell is reduced leading to senescence. Von
Zglinicki in his review of oxidative stress and telomere length acknowledged that in most
cases the replicative senescence of telomeres is a stress response arising from external
oxidative stress or diminished internal antioxidant defenses. His review of experiments
on stress dependency of telomere shortening revealed that 19 out of 22 independent
experiments from seven different laboratories, showed increased telomere shortening rate
under conditions of increased oxidative stress. He further suggested that telomere length
might serve as a biomarker of cumulative exposure to oxidative stress and a prognostic
indicator for risk of late-life diseases89.

1.7 Summary
In summary, reactive oxygen species have been widely accepted as a major
contributor to dysfunction of biological systems resulting in aging and age-related
diseases. In this dissertation, factors that encourage increased reactive oxygen species
production were investigated. Sleep-disordered breathing and CML are both associated
with oxidative stress; hence, this dissertation investigated the relationship between sleepdisordered breathing and serum CML concentration. CML accumulation has been
association with Alzheimer’s disease, end-stage renal disease, hypertension,
atherosclerosis and many other age-related disorders. Understanding its association with
sleep disordered breathing could provide avenues for prevention. In addition, we
investigated the role of sleep and obesity on type-2 diabetes risk. Diabetes results from
oxidative damage to insulin producing cells and research suggests that sleep disturbances
and obesity may be involved in this process. Lastly, we investigated the effects of alcohol
consumption and obesity on telomere length. Telomere shortening has been found to be
12

stress dependent and alcohol consumption and obesity can induce stress. Telomere
shortening has been linked to neurodegenerative diseases, infections, diabetes,
malignancies, atherosclerosis, and cardiovascular disease. Understanding the sources of
stress in telomere shortening is important in the wake of the harmful effects of shorter
telomeres on health.
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Figure 1: Mechanisms linking oxidative stress to aging and degenerative diseases
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CHAPTER TWO

THE RELATIONSHIP BETWEEN SLEEP-DISORDERED BREATHING AND NϵCARBOXYMETHYL-LYSINE CONCENTRATION IN THE CARDIOVASCULAR
HEALTH STUDY

2.1 INTRODUCTION
Advanced glycation end-products (AGEs) have been implicated in pathologies
such as diabetic microvascular disease, rheumatoid arthritis, Alzheimer’s disease, endstage renal disease, hypertension, atherosclerosis and other late-life disorders39. Major
AGEs include hydroimidazolone (HI), Nϵ-carboxymethyl-lysine (CML), pentosidine
(PTD), and glucosepane39. CML is the focus in this study because it has been found to be
a general biomarker of oxidative stress and damage in tissue proteins. CML is formed on
protein by combined nonenzymatic glycation and oxidation reactions, and also during
metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of protein42.
CML has serious implications for cardiovascular disease because it has been found to be
the main contributor to atherosclerotic plaque42, 90, 91. Cardiovascular disease is the
leading cause of death in the United States. More than 80 million people live with
cardiovascular disease of some sort, and together with stroke they account for more than
$500 billion in medical costs in 2010. It is important that the scientific community find
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ways to reduce accumulation of advanced glycation end-products, including CML, as
part of efforts aimed at reversing the trend of cardiovascular morbidity and mortality.
There is a possible link between sleep-disordered breathing and serum CML
levels because sleep-disordered breathing is accompanied by production of free radicals
and increased oxidative stress, a condition which promotes increased CML production. In
sleep-disordered breathing there are repeated episodes of hypoxia which leads to energy
crisis as the production of adenosine triphosphate (ATP) is impaired leading to upregulation of glycolysis and consequent increased production of reactive oxygen species
(ROS)24, 92. Sleep-disordered breathing, especially obstructive sleep apnea, can be treated
by use of continuous positive airway pressure (CPAP)93-96. This implies that if evidence
exists for a causal relationship, then intensification of efforts to promote sleep hygiene
and treatment of sleep-disordered breathing could be considered as part of efforts to
reduce CML accumulation and hence reduce cardiovascular and other age-related
diseases.
Few studies investigated the effect of sleep-disordered breathing on AGEs,
broadly96, 97. A pilot study has also shown that continuous positive airway pressure
treatment reduces serum AGEs in patients with obstructive sleep apnea syndrome98. The
relationship between sleep disordered breathing and CML concentration however has not
been studied. Moreover, there is evidence for increased lipid peroxidation biomarkers, an
indication of increased state of oxidative stress, in sleep-disordered breathing 99. Since
CML is formed from lipid peroxidation and known to be an excellent biomarker for
oxidative stress it will be more appropriate to investigate the association between sleepdisordered breathing and CML specifically instead of AGEs as a broad category. The
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main aim of this study is to investigate the association between sleep-disordered
breathing and serum CML levels in the Cardiovascular Heart Study.

2.1.1 Study objectives
1. To investigate the cross-sectional relationship between sleep disordered breathing
(SDB) assessed by apnea-hypopnea index (AHI), and carboxymethyl-lysine
(CML) concentration in the Cardiovascular Heart Study (CHS) cohort enrolled in
the Sleep Heart Health Study (SHHS).

2. To investigate the potential modification effects of gender and hemoglobin on the
association between sleep disordered breathing and CML.

2.1.2 Hypotheses
1. Study subjects with SDB will have higher serum concentrations of CML.
2.

The effect of SDB on CML concentration will vary by gender and will be higher
in participants with higher hemoglobin levels.

2.1.3 Justification of the study
Carboxymethyl-lysine (CML), a well characterized advanced glycation endproduct has been associated with degenerative diseases including Alzheimer’s disease,
end-stage renal disease, hypertension, atherosclerosis and many other age-related
disorders. Pharmaceutical interventions to reduce CML accumulation have shown
promising results but are yet to be investigated using larger populations. Continuous
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positive airway pressure (CPAP) treatment for sleep-disordered breathing, especially
obstructive sleep apnea, has been established. Evidence for a causal relationship between
sleep-disordered breathing and CML could provide avenue for intervention within the
wide range of possible interventions.

2.2 METHODS
2.2.1 Study Design: Population-based cross-sectional study of the association between
sleep-disordered breathing and serum carboxymethyl-lysine.
2.2.2 Study Participants: The subjects for this study are CHS cohort members who were
enrolled in the SHHS. The CHS is a population-based longitudinal study designed to
determine the risk factors for development and progression of cardiovascular disease
(CVD) in older adults (≥65 years) in the United States. The CHS recruited 5,888 adults
from four U.S communities: Forsyth County, North Carolina; Sacramento County,
California; Washington County, Maryland; and Pittsburgh, Pennsylvania. The SHHS is a
prospective cohort study designed to investigate obstructive sleep apnea (OSA) and other
sleep-disordered breathing (SDB) as risk factors for the development of cardiovascular
disease. Participants in SHHS were recruited from already existing cohort studies:
Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Framingham
Heart Study, Strong Heart Study, New York Hypertension Cohorts, and Tucson
Epidemiologic Study of Airways Obstructive Diseases and the Health and Environment
Study. Participants in the SHHS underwent home polysomnography to assess the
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presence of OSA and other SDB100. This study focuses on over 1000 participants that
were recruited from the CHS into the SHHS.

2.2.3 Assessment of Sleep Disordered Breathing
SDB was diagnosed by polysomnography and measured by apnea-hypopnea
index (AHI). AHI is the number of respiratory events scored per hour of sleep. Apneas
and hypopneas were classified according to the American Academy of Sleep Medicine
(AASM) criteria. According to AASM criteria an event is classified as apnea if there is a
drop in peak thermal sensor excursion by ≥90% from baseline, for 10 seconds or greater,
and an event is classified as hypopnea if there is a ≥30% drop in the nasal pressure
excursion for 10 seconds or greater associated with ≥ 4% desaturation 101, 102. AHI was
used as a continuous variable and cut-points were also be considered. AHI cut points for
diagnosis are: <5/hr (normal), ≥ 5 and < 15/hr (Mild), ≥ 15 and ≤ 30/hr (moderate), and
AHI > 30/hr (severe) 103.

2.2.4 Polysomnography
Polysomnography (PSG) or a sleep study is a test used to diagnose sleep
disorders. It is considered to be the ‘‘gold standard’’ for diagnosing SDB and other sleep
disorders. PSG monitors sleep stages and cycles to identify disruptions in sleep patterns.
PSG is recommended when the following are suspected: sleep-related breathing disorder,
periodic limb movement disorder, narcolepsy, unusual behaviors during sleep, and
unexplained chronic insomnia. PSG is a noninvasive test. However the adhesive used to
attach the test sensors to the skin could cause skin irritation. Alcohol and caffeine may
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make symptoms of some sleep disorders worse and it is recommended that they are
avoided at least 12 hours before the sleep study.
There are two critical components of PSG: (1) determination of sleep-wake stage,
and (2) identification of related bodily processes. Sleep-wake determination involves
electroencephalography (EEG; records surface electrical activity of the brain),
electrooculogram (EOG; records eye movements during sleep and wakefulness), and
electromyography of the submentalis (EMG; recordings are essential for scoring sleep
stages)104. The placement of these electrodes is shown by Appendices 1, 2, and . Related
bodily processes measured in PSG include heart rate, blood pressure, and respiratory
function. Respiratory air flow is determined by measuring inhaled and exhaled air
temperatures by a thermistor. Thermosensors are best in determining apneas because they
are very sensitive to even minor air flow. They are however poor detectors of partial flow
limitations (hypopneas) because even slight air flow produces large amplitude deflections
due to their high sensitivity. Apart from thermosensors, nasal pressure can be measured
by piezoelectric pressure sensors which are very sensitive to hypopneas. Appendix 4
shows the placement of nasal pressure cannulae104, 105.
Relevant parameters measured in PSG include total recording time, total sleep
time, sleep period time, time in bed, sleep efficiency, sleep latency and REM sleep
latency, and sleep stage distribution. A summary of the entire night’s PSG data can be
presented in a graphic form called a sleep hypnogram. Appendix 5 shows a sleep
hypnogram of normal and fragmented sleep patterns105.

20

This study used sleep study data of subjects who underwent home PSG. Apneahypopnea index (AHI) was scored according to the guidelines of the American Academy
of Sleep Medicine101.

2.2.5 Formation of Advanced Glycation End-products (AGEs)
AGEs are formed when reducing sugars react non-enzymatically with amino
groups in proteins, lipids, and nucleic acids. This involves series of reactions in which
Schiff bases undergo Amadori rearrangement to form the Amadori product. The Amadori
product undergoes further reactions to generate AGEs. This process is also called the
Maillard reaction (browning reaction) and was identified in 1912 when it was found that
a characteristic yellow-brown color was developed when amino acids were heated in the
presence of reducing sugars41. CML is one of the dominant AGEs and known to be a
glycoxidation product because it is formed by both oxidation and glycation reactions106.
CML is also formed as a product of lipid peroxidation42. Glycoxidation and lipoxidation
reactions are accompanied with reactive oxygen species production; hence CML has been
characterized as a general biomarker of oxidative stress. A schematic presentation of
AGE formation pathways is shown in Appendix 6.
2.2.6 Measurement of CML
CML was measured as described by Barzilay et al107. Briefly, fasting samples
were stored at -80 degrees Celsius and CML measured using a competitive enzymelinked immunosorbent assay (ELISA); AGE-CML ELISA, Microcoat, Penzberg,
Germany.
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2.2.7 Selection and Definition of Covariates
The following variables were collected for use in this study because previous
research has shown their association with either sleep disordered breathing (SDB) or
CML accumulation: age, sex, race, smoking, alcohol intake, BMI, hypertension, diabetes,
household income, physical activity, general health status, insomnia, estimated
glomerular filtration rate (eGFR), C-reactive protein, hemoglobin, HDL cholesterol,
prevalent MI, CHD, stroke, and claudication. Some of these variables were used as
continuous variables and others were used as categories. Age as a categorical variable
was classified as 64-69, 70-74, 75-79, and 80 years or more. Race and ethnicity was
classified as “White”, “African American or Black”, and “other”. The “other” class
includes American Indian or Alaskan native, Asian or Pacific Islander. BMI was
categorized according to the World Health Organization guidelines as “normal” (BMI
<25.0 kg/m2), “overweight” (BMI 25-29.9 kg/m2), or “obese” (BMI ≥30 kg/m2).
Smoking status was categorized as “nonsmoker”, “former smoker”, or “current smoker”,
and blood pressure was categorized into “normal”, “prehypertension”, or “hypertension”
according to the Seventh report of the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) criteria.
According to this guideline a normal blood pressure has systolic pressure of less than 120
mmHg and a diastolic pressure of less than 90 mmHg, prehypertension is systolic blood
pressure of 120 to 139 mmHg or diastolic pressure of 80 to 89 mmHg, and hypertension
is systolic pressure of 140 and above or diastolic pressure of 90 and above. Self-reported
health status was categorized as “excellent”, “very good”, “good”, “fair”, or “poor” and
diabetes status was defined based on the American Diabetes Association guidelines. The

22

2-hour glucose test (oral glucose tolerance test-OGTT) was used and diabetes was
defined as 2 hour blood glucose of greater than or equal to 200 mg/dl, impaired fasting
glucose (prediabetes) was defined as 2 hour blood glucose of ≥140 to <200 mg/dl, and
normal was defined as 2 hour blood glucose of less than 140 mg/dl. The status of
conditions such as MI, CHD, CHF, stroke, Claudication, and insomnia were coded as
“yes” or “no”, and exercise intensity was categorized as “none”, “low”, “moderate”, or
high. Household income of participants was put into 5 classes: <$12,000, $12,000$24,999, $25,000-$49,999, $50,000-$75,000, and >75,000.
2.2.8 Inclusion and Exclusion Criteria
A total of 2287 participants in the CHS have CML records but since the exposure
of interest is sleep disordered breathing (SDB) assessed by apnea-hypopnea index (AHI),
we excluded all participants without AHI records. A total of 1285 participants without
AHI records were excluded leaving a sample size of 1002 that was used in this analysis.
2.2.9 Statistical Analysis
CML was measured between 1996 and 1997 (CHS year 9) around the same time
that polysomnography was conducted on the participants. Linear regression was used to
test the cross-sectional relationship between SBD (assessed by AHI) and CML
concentration. CML distribution was skewed to the right and was log transformed before
analysis. SDB (AHI) was the exposure variable and serum CML concentration was the
outcome variable. The following were adjusted for: age, sex, race, smoking, alcohol
intake, BMI, hypertension, estimated glomerular filtration rate (eGFR), C-reactive
protein, hemoglobin, HDL cholesterol, prevalent MI, CHD, stroke, and claudication. This
parsimonious set of variables was arrived at through a model building technique
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recommended originally by Hosmer and Lemeshow108, and described further by
Jewell109. It involves examining risk factors in order of their primary interest in terms of
relationships with the outcome or main predictor, and checking for possible interactions.
Stratified analyses based on gender and hemoglobin were performed with adjustment for
the confounders mentioned above. Measurements from previous years were used to
impute missing values. All analyses were performed using SAS version 9.3. Levels of
significance of all analyses were based on p-value of 0.05.

2.2.10 Power Calculation (SDB and CML)
2.2.11 Prevalence of sleep apnea in the study population
More than 18 million adults in America have sleep apnea according to the
National Sleep Foundation (NSF)110. The NSF also found that individuals ≥40 years are
at increased risk of sleep apnea. Using the 2010 U.S census111, approximately 124 million
residents were ≥40 years old. Hence 18 million adults with sleep apnea will amount to
approximately 15% of the population ≥40 years. The CHS cohort is made up of
individuals that are ≥65 years of age, and moderate to severe (AHI ≥15) sleep disordered
breathing was found in 35.2% of the sample. With 1002 participants this results in an
exposed group of 353 and unexposed group of 649.
2.2.12 Prevalence of high CML among exposed and unexposed groups
CML is a metabolic by-product and increased accumulation increases the risk of
health problems. An investigation into the effect of CML on the risk of hip fracture in the
CHS showed that all but the first quartile showed increased risk of hip fracture107. This
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implies the 2nd, 3rd, and 4th quartiles of CML could be regarded as “high” (that is, 75% of
the population, and in this case ≥65 year olds). In another study the association between
CML (categorized as “Low” or “High” at the median) and carotid diameter was
investigated and it was found that “high” CML was associated with enlarged carotid
diameter112. In this case 50% of the study participants were classified as having “high”
CML.
With 95% confidence level, 35.2% prevalence of sleep apnea, 75% “high” CML
in the study population (unexposed), and 83% “high” CML in the study population
(exposed), the power of the study is more than 80% as presented in table 1.
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Table 1: Power calculation for the association between sleep disordered breathing
and carboxymethyl-lysine (based on 75% of study population with high CML)
Power for Cross-Sectional Studies (SDB and CML)
Exposed Group
Unexposed Group
Sample Size

353

649

Prevalence (or) Coverage (%)

83

75

Power based on:
Normal approximation

83.04%

Normal approximation with continuity
correction

80.91%

With 95% confidence level, 35.2% prevalence of sleep apnea, 50% “high” CML
in the study population (unexposed), and 59.4% “high” CML in the study population
(exposed), the power of the study is at least 80% as presented in table 2.

Table 2: Power calculation for the association between sleep disordered breathing
and carboxymethyl-lysine (based on 50% of study population with high CML)
Power for Cross-Sectional Studies (SDB and CML)
Exposed Group
Unexposed Group
Sample Size

353

649

Prevalence (or) Coverage (%)

59.4

50

Power based on:
Normal approximation

81.4%

Normal approximation with continuity
correction

79.54%
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2.3 RESULTS
A total of 1002 subjects were involved in this study. The mean age was 77.5 and
28% were 80 years and above [Table 3]. The sample was predominantly Caucasian
(81%), and made up of 57% females. The mean BMI of participants was 27.2 kg/m2 with
normal, overweight, and obese subjects forming 31.4%, 46.9%, and 21.7%, respectively.
Nondrinkers constitute 56.7% of the sample and among drinkers the average alcohol
consumption per day was 10gm. Non-smokers represent 48.6% of the sample and 6.3%
of the sample were current smokers. Participants had mean hemoglobin of 13.8 g/dl, and
by gender it was 13.3 g/dl and 14.4 g/dl for females and males respectively. The mean Creactive protein (CRP) concentration was 5.0 mg/L, and the mean estimated glomerular
filtration rate (eGFR- cystatin C) was 82.4 mL/min/1.73 m2. The percent of sleep time of
SaO2 below 90% was on average 4.3 among the study participants and about 21 arousals
were experienced on average per hour of sleep. The mean CML concentration among
study participants was 6161.2 ng/ml (6.4 ng/ml after log transformation), and participants
experienced on average 11.5 apneas and hypopneas per hour of sleep. Participants who
earned $50,000 or more, had moderate to high physical activity, high blood pressure
(≥140/90), self-reported good health or better, and impaired fasting glucose or diabetic
formed 16.3%, 53.9%, 52.3%, 83.6%, and 24.4%, respectively, of the sample.
Participants who had MI, CHD, CHF, stroke, claudication, and insomnia formed 9.8%,
24.0%, 6.8%, 4.0%, 2.8%, and 18.9%, respectively, of the sample [Table 3].

27

In unadjusted analyses, BMI, % sleep time of SaO2 below 90%, arousal index,
HDL, and eGFR- cysC, were significantly associated with sleep disordered breathing
(SDB) measured by Apnea-Hypopnea Index (AHI) [Table 3]. Whilst increasing values of
BMI, % sleep time of SaO2 below 90%, and arousal index were associated with
increasing severity of SDB, decreasing values of HDL and eGFR- cysC, were associated
with increasing severity of SDB. Hemoglobin has a borderline significance with SDB
(p=0.069) in this unadjusted model and higher levels were associated with increasing
severity of SDB. Other variables that were significantly associated with SDB in the
unadjusted model include race/ethnicity, gender, prevalent MI status, and prevalent CHF
status. African Americans, males, MI patients, and CHF patients were more likely to
have severe SDB [Table 3]. Variables which significantly influenced CML accumulation
in the unadjusted models were age, BMI, alcohol use, HDL, triglycerides, hemoglobin,
eGFR- cysC, arousal index, and smoking status. Higher levels of CML were associated
with increasing age, and HDL but with decreasing BMI, alcohol use, triglycerides,
hemoglobin eGFR- cysC, and arousal index. Current smoking status was significantly
associated with lower CML levels in the unadjusted analysis [Table 4].
Sleep disordered breathing was not associated with CML in either the unadjusted
or adjusted models [Table 5]. However, modification effects by gender and hemoglobin
on the association between SDB and CML were identified [Table 6]. The variables in the
main effects model include apnea-hypopnea index, age, BMI, gender, race, alcohol,
smoking, stroke, claudication, CHD, MI, diabetes, hypertension, HDL, hemoglobin,
CRP, and eGFR. As shown in table 4, the model with the 3-way interaction appears to the
best model for this analysis. Taking the 3-way interaction into consideration, it was found
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that among males with hemoglobin concentration greater than 14.29 g/dl, there was an
inverse relationship between SDB and CML concentration, while among females with the
same hemoglobin level there was a direct relationship between SDB and CML
concentration [Table 7]. Interaction effects by diabetes and insomnia were investigated
but were not significant.
2.3.1 Males with hemoglobin concentration >14.29 g/dl
Compared to male subjects with no SDB, males with severe SDB have 16.1%
lower CML concentration if hemoglobin is >14.29 g/dl (p=0.0146). There was no
significant association between SDB and CML concentration among males with
hemoglobin ≤14.29 g/dl [Table 7].
2.3.2 Females with hemoglobin concentration >14.29 g/dl
Compared to female subjects with no SDB, females with severe SDB have 28.1%
higher CML concentration if hemoglobin is >14.29 g/dl (p=0.0336). Also, compared to
female subjects with no SDB, females with mild SDB have 19.0% higher CML
concentration if hemoglobin is >14.29 g/dl (p=0.0061). There was no significant
association between SDB and CML concentration among females with hemoglobin
≤14.29 g/dl [Table 7].
2.3.3 The effect of hemoglobin (irrespective of gender) on the SDB-CML association
Considering the fact that an interaction between SDB (AHI) [Table 6] and
hemoglobin was detected and that hemoglobin is highly influenced by gender, an
alternative approach was to find those hemoglobin cut-points where the influence of SDB
on CML becomes clinically important. This was done by performing analyses with

29

different hemoglobin cut-points until the association between SDB and CML becomes
significant. The following cut-points have been identified and apply to both males and
females: <12.7 g/dl, 12.7 to <14.6 g/dl, and ≥14.6 g/dl.

2.3.4 The effect of hemoglobin <12.7 g/dl (irrespective of gender) on the SDB-CML
association
There was no significant association between SDB and CML concentration for
hemoglobin <12.7 g/dl [Table 8].

2.3.5 The effect of hemoglobin 12.7-14.59 g/dl (irrespective of gender) on the SDBCML association
Among subjects with hemoglobin concentration between 12.7 and <14.6 g/dl, it
was found that subjects with severe SDB were more likely (9.1%; p=0.0318) to have
higher CML concentration compared to subjects with no SDB. It was also found within
the same hemoglobin class that subjects with mild SDB were more likely (5.9%;
p=0.0223) to have higher CML concentration compared to subjects with no SDB [Table
8].
2.3.6 The effect of hemoglobin ≥14.6 g/dl (irrespective of gender) on the SDB-CML
association
Among subjects with hemoglobin concentration ≥14.6 g/dl, it was found that
subjects with severe SDB have significantly lower CML concentration (13.8%;
p=0.0364) compared to subjects with no SDB [Table 8].
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2.4 DISCUSSION
The multivariable models did not detect significant association between sleep
disordered breathing (SDB) and carboxymethyl-lysine (CML) concentration. It was
found however that the association between SDB and CML was modified by gender and
hemoglobin. At high hemoglobin levels females with SDB have higher levels of CML
whilst males with SDB have lower levels of CML. This study is the first of its kind with
no previous studies to compare the findings to. However, a few studies investigated the
association between SDB and advanced glycation end-products broadly.
In one study conducted by Lam et al.,96 among 105 males (mean age 43.5 years)
without diabetes, significantly higher serum advanced glycation end-product (AGE)
levels were observed in subjects with SDB (AHI ≥5), compared to subjects without SDB
(AHI <5). They also found that among subjects with moderate to severe SDB who
underwent CPAP treatment, serum levels of advanced glycation end-products were
decreased indicating a direct relationship between SDB and advanced glycation endproducts. This is contrary to the lower CML concentration in severe SDB found among
males with high hemoglobin in our study. The difference in findings could arise from the
differences between CML (a specific AGE) and AGEs in general. In addition, we
stratified on hemoglobin but Lam et al. did not. Furthermore, Lam et al. studied a
younger population (mean age: 43.5 years) while we studied a much older population
(mean age: 77.5 years) which could potentially contribute to differences in the findings.
Tan et al.97 investigated the association between SDB and advanced glycation
end-products in a case-control study involving 119 nondiabetic patients with SDB and
234 age-matched healthy controls. They found that markers of oxidative stress increased
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in SDB patients and serum levels of advanced glycation end-products increased. The
studies by Tan et al., and Lam et al. were consistent in establishing a direct relationship
between SDB and advanced glycation end-products. We found a direct relationship
among females but not males, and only after hemoglobin stratification. CML is a well
characterized advanced glycation end-product, and has been described as the general
biomarker of oxidative stress. Hence a direct relationship between SDB and CML is
expected but our data only partially supports that hypothesis.
2.4.1 Mechanisms linking sleep disordered breathing to CML concentration
Revisiting our hypothesis of free radical production thorough the xanthine oxidase
pathway and how that might affect CML accumulation, it has been established that SDB
is characterized by intermittent hypoxia and re-oxygenation after each hypoxic episode
generates free radicals. Overproduction of free radicals leads to a state of oxidative stress
and could accelerate CML production. The modification effect by gender is plausible
because in premenopausal women estrogen is very active in scavenging free radicals, and
also has the ability to stimulate enzymes to detoxify free radicals. This implies that in
premenopausal women, one could expect reduced CML accumulation compared to males
even in sleep disordered breathing situations. In this study the mean age was 73.5 years
with minimum of 64 years and a maximum of 95 years. Therefore the women in this
study are all postmenopausal and unless they all use estrogen replacement therapies, one
should not expect the protective effect of estrogen on free radicals among women in this
study. Significant effects of SDB on CML concentration was found but only at high
hemoglobin levels and these effects differ by gender. Among females with hemoglobin
concentration >14.29 g/dl, increased CML concentration was associated with mild and
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severe SDB [Table 7] and this supports our hypothesis that increased free radical
production in SDB could lead to increased CML accumulation; this was not the case for
males. Focusing more on this result among females, what could be the possible reasons
why the effect of SDB on CML was only significant at the higher spectrum of
hemoglobin?
Circulating ferrous hemoglobin participates in chemical reactions that could be
toxic in living organisms. Among these reactions is autoxidation of oxy-hemoglobin.
Oxy-hemoglobin undergoes a slow, but spontaneous intramolecular redox reaction, in
which the heme iron is oxidized to the ferric form and oxygen reduced to superoxide113116

:

Hb2+O2 → Hb3+ + O2•-

In the presence of adequate antioxidant defense systems, the superoxide will be
dismutated to oxygen and hydrogen peroxide by superoxide dismutase:

2O2•- + 2H+ → O2 + H2O2
In the absence of antioxidant enzymes these reactions could promote hydroxyl radical
formation via the following reactions26:
Fenton reaction: Fe2+ + H2O2 → Fe3+ + OH• + OH- or the
Haber–Weiss mechanism: O2•- + H2O2 → OH• + OH- + O2; catalyzed by Fe3+
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Intermittent hypoxia followed by re-oxygenation which occurs in sleep disordered
breathing (SDB) generates superoxide28, 29 and hemoglobin serves as the source of iron
which catalyzes the reactions leading to the more potent hydroxyl radical113. CML is a
biomarker of oxidative stress and accelerated CML production as a result of increased
free radicals at high hemoglobin levels is plausible. The increased CML production at
high hemoglobin levels occurred mainly in females and not in males because in
postmenopausal women (as in this study), iron stores tend to increase rather than decrease
(Appendix 7)117. Ferritin, an intracellular protein that stores iron and controls its release
has been found to increase whiles estrogen decrease during the menopausal transition
(Appendix 8)118.
The increase in body iron in females after menopause has oxidative burden
consequences. This is because menopause is accompanied with increase in body weight,
decreased antioxidant defenses and chronic inflammation119. This results in increased free
radical production and reduced antioxidant defenses in postmenopausal women, a
situation of oxidative stress. Oxidative stress from increased free radicals in SDB at high
hemoglobin levels in postmenopausal women is a plausible cause of the increased CML
concentration found in these individuals. A schematic presentation of iron increase during
menopause and oxidative stress is shown in Appendix 9.
Among males SDB was significantly inversely associated with CML
concentration at hemoglobin >14.29. In other words SDB (severe) was found to be
associated with lower CML concentration. This is the first study examining the
relationship between SDB and CML hence there are no comparative studies for this
observation. However, there are plausible explanations for this association. Males have
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higher hemoglobin concentration than females and are expected to generate more reactive
oxygen species in the presence of SDB and hence increased CML accumulation.
However, the reverse was observed and may partly be due to unmeasured
carboxyhemoglobin (COHb) in males. Cigarette smoking raises the blood levels of
COHb resulting in reduced hemoglobin which interrupts oxygen transport from the lungs
to the rest of the body120. Hence unlike females whose iron stores increase after
menopause, older males are more likely to be anemic due to tobacco use and that could
influence the effect of hemoglobin on the SDB and CML association. Results from this
study have shown that males were significantly likely than females to be smokers (p
<.0001) [Figure 2] which adds evidence to the COHb hypothesis.
Figure 2: Percent of males and females in each smoking category

Apart from the hindrance of hemoglobin function by COHb, older males could
actually suffer reduced hemoglobin due to colorectal cancer121, 122. An estimated 71,830
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men and 65,000 women will be diagnosed with colorectal cancer and 26,270 men and
24,040 women will die of the disease in 2014, according to the National Center for
Health Statistics123. Females can build up their iron stores after menopause but males
cannot and the associated iron deficiency in males could play an important role in
reducing oxidative stress and hence the observed lower CML concentration with SDB124.
Physical activity has been found in many studies to protect against oxidative
stress, especially in older individuals and could also account for the association between
SDB and CML concentration in males with hemoglobin >14.29g/dl. A study by
Traustadóttir et al.,125 tested the hypothesis that physically fit older adults would have
less oxidative stress than unfit age-matched controls. They recruited 37 fit individuals
with an average age of 65 years, and 35 unfit individuals with an average age of 67.7
years, and found that fit individuals had significantly lower oxidative stress markers
compared to the unfit individuals. Our results have shown that males were more likely
than females to engage in moderate to high physical activity (p=0.0028), as shown on
figure 3. More specifically, it was found that males with hemoglobin above 14.29 g/dl
were significantly more likely than females in the same hemoglobin group, to engage in
moderate to high physical activity (p=0.0391), as shown on figure 4. These findings
might explain the protective effect of SDB on CML concentration found among males
with hemoglobin >14.29 g/dl.
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Figure 3: Percent of males and females in each exercise intensity category

Figure 4: Percent of males and females by exercise intensity: hemoglobin >14.29 g/dl
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These findings are also consistent with findings by Karolkiewicz et al.,126 who
studied the relationship between markers of oxidative stress and physical activity among
men (mean age: 73.4 years). They found that compared with less active men, more active
men have higher plasma levels of glutathione (GSH), indicating favored antioxidant
potential, and lower thiobarbituric acid reactive substance (TBARS) concentration,
indicating inhibited lipid peroxidation. Pierce et al.,127 also came to the conclusion that
physical activity protects against the harmful effects of oxidative stress when they
compared older men who perform habitual aerobic exercise with their sedentary
counterparts.
The lower CML concentration found among males with severe SDB at high
hemoglobin levels may not necessarily be a protective effect of severe SDB. Life
expectancy for males and females in the United States is approximately 77 and 82 years,
respectively, and we studied a population with mean age of 77.5 years. It is likely that
males with severe SDB and who by our hypothesis should have high CML levels have
died before CML was measured for this analysis. Hence we may be looking at males who
even with SDB have survived for reasons beyond the scope of this study, and their CML
values may not be reflective of what would be observed if a younger population were
studied.
2.4.2 The effect of hemoglobin on the association between SDB and CML
The 3-way interaction between gender, hemoglobin, and SDB on the CML
concentration has been discussed above. However in table 7 we sought to find
hemoglobin levels at which the effect of SDB on CML concentration would be clinically
important. New hemoglobin cut-points have been created for the entire sample without
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gender stratification. Mild and severe SDB were significantly associated with higher
CML concentrations in the normal hemoglobin class (12.7-14.59 g/dl). This normal
hemoglobin class involved more than half of the entire study sample and divided among
males and females as 37% and 63%, respectively. Although this hemoglobin level
appears to be important clinically in terms of CML accumulation and consistent with our
hypothesis, the unequal representation of gender raised concerns. This is because female
gender has been associated with increased CML concentration in the presence of SDB (at
hemoglobin >14.29 g/dl) [Table 6] and since females have dominated this normal
hemoglobin class (63%), it is likely that the association observed in this hemoglobin class
is due to female gender. In the high hemoglobin class (≥14.6 g/dl) [Table 8] severe SDB
was associated with lower CML concentration. This high hemoglobin class was made up
of 77.6% males. It is also likely that male gender influenced the direction of the
association between SDB and CML concentration. Nevertheless, these results further
strengthen the importance of the gender effect observed in table 7. The hemoglobin
cutpoints in table 6 will need to be tested with a much larger sample such that each class
has adequate representation of males and females. If significant associations disappear
after equal representation of gender in the hemoglobin classes, then the 3-way interaction
between gender, hemoglobin, and SDB (as done in table 7) will be the best approach for a
study examining the relationship between SDB and CML concentration.
2.4.3 Strengths and Limitations
Strengths of this paper include firstly, the reliability of the data. This study was
conducted in the cardiovascular health study (CHS) initiated by the National Heart, Lung
and Blood Institute, and has extensive clinical data with participants coming from four
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U.S communities. More than 1000 research papers have been published in peer reviewed
journals since the cohort began giving credibility to the dataset and hence our findings.
Secondly, our findings support the hypothesis that oxidative stress from SDB affects
CML accumulation. Although the association between SDB and CML has not been
studied, our findings are consistent with studies that investigated the effects of factors
like smoking, physical activity, and hemoglobin on oxidative stress. Limitations of this
study include its cross-sectional nature. Ethical reasons will not allow for a prospective
study between SDB and CML concentration since SDB can be treated. However, a
second or more CML measurements with time may help to retrospectively study
longitudinal effects of SDB on CML accumulation. This study included only subjects
with AHI records limiting our sample size to 1002. A larger sample may be instrumental
in establishing the validity of the findings. Lastly, there are no studies on the association
between SDB and CML for comparison. Availability of such a study could provide some
useful clues on the best modelling approach for the association. Nevertheless, the
approaches used in this study are consistent with published literature and would pave the
way for future researchers.
2.4.4 Recommendations for Future Research
Future studies would be needed to further investigate the inverse relationship
between SDB and CML accumulation that was observed at high hemoglobin levels
among males. A larger sample size will be useful to confirm such an association. Also, it
will be important to measure carboxyhemoglobin in males to verify if the interaction
between hemoglobin and SDB persists and if SDB protects against increased CML
concentration as was observed in this study at high hemoglobin levels. Lastly, future
40

studies to test the association between SDB and CML concentration at hemoglobin levels
of <12.7 g/dl, 12.7-14.29 g/dl, and >14.29 g/dl, will be important in establishing the role
of gender in the association between SDB and CML concentration.

2.5 CONCLUSION
CML levels have been linked to disease, particularly cardiovascular disease.
Findings from this study have indicated that CML level depends on a complex interplay
of factors such as gender, hemoglobin, and sleep disordered breathing. Sleep disordered
breathing is characterized by production of free radicals and hemoglobin serves as the
source of iron that catalyzes the reactions resulting in the increased CML concentration
found at high hemoglobin levels. The protective effect of SDB found among males could
be attributed to physical activity which is common among older men resulting in reduced
oxidative stress and hence lower CML. Cigarette smoking among males has also been
hypothesized to reduce oxidative stress because more carboxyhemoglobin is produced
inhibiting the reactions of hemoglobin in promoting free radicals. These findings have
public health implications because SDB can be treated and antioxidant defenses systems
can be upregulated through physical activity to lower CML accumulation and hence
reduce diseases that arise from oxidative damage.
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Table 3: Characteristics of up to 1002 participants from the Cardiovascular Health Study
by severity of SDB
N
1002
990
988
968
963
982
985
978
972
925
1002
959

Normal
77.2 (4.4)
N=396
26.7
(4.3)
3.4 (6.6)
203 (36.5)
128 (34.1)
55.1 (15.2)
141 (79.8)
13.7(1.4)
5.2 (9.9)
83.6(19.0)
1.8 (8.3)
17.2 (9.3)

AHI
Mild
Moderate
77.7 (4.5)
77.7 (4.3)
N=353
N=162
27.2
(4.2)
27.9
(4.2)
5.2 (11.4)
4.6 (10.9)
200 (41.0)
202 (40.9)
127 ( 34.4)
130 (29.9)
53.2 (13.9) 51.2 (13.9)
147 (100)
149 (88.1)
13.7 (1.4)
13.9 (1.3)
4.6 (8.9)
5.7 (10.2)
83.7 (18.8) 78.0 (17.3)
3.8 (11.6)
6.7 (12.6)
19.2 (8.8)
25.0 (11.3)

263
455
284

114 (28.8)
174 (43.9)
108 (27.3)

88 (24.9)
160 (45.3)
105 (29.8)

41 (25.3)
75 (46.3)
46 (28.4)

20 (22.0)
46 (50.6)
25 (27.5)

Male
Female

429
573

130 (32.8)
266 (67.2)

157 (44.5)
196 (55.5)

85 (52.5)
77 (47.5)

57 (62.6)
34 (37.4)

37.3 (<.0001)

White
Black/AA
Other

816
179
7

313 (79.0)
82 (20.7)
1 (0.3)

294 (83.3)
56 (15.9)
3 (0.8)

141 (87.0)
20 (12.4)
1 (0.6)

68 (74.7)
21 (23.1)
2 (2.2)

0.0330*

BMI (kg/m2)
Normal
Overweight
Obese

311
464
215

147 (37.5)
175 (44.6)
70 (17.9)

101 (29.2)
173 (50.0)
72 (20.8)

41 (25.5)
78 (48.5)
42 (26.0)

22 (24.2)
38 (41.7)
31 (34.1)

20.9 (0.0019)

Smoking Status
Non-smoker
Former smoker
Current smoker

485
449
63

196 (49.5)
169 (42.7)
31 (7.8)

162 (46.4)
170 (48.7)
17 (4.9)

85 (52.5)
71 (43.8)
6 (3.7)

42 (46.7)
39 (43.3)
9 (10.0)

8.9 (0.1799)

168
333
293
89
66

68 (18.0)
145 (38.4)
112 (29.6)
28 (7.4)
25 (6.6)

63 (18.8)
98 (29.2)
104 (30.9)
45 (13.4)
26 (7.7)

21 (13.8)
61 (40.1)
50 (32.8)
9 (5.9)
11 (7.2)

16 (19.3)
29 (34.9)
27 (32.5)
7 (8.4)
4 (4.8)

18.0 (0.1159)

Variable
Age (years), mean (s.d)
BMI (kg/m2)
Alcohol (GM)
Cholesterol(mg/dl)
Adjusted LDL (mg/dl)
HDL (mg/dl)
Triglyceride (mg/dl)
Hemoglobin (g/dl)
C-reactive protein (mg/L)
eGFR-cysC
% Sleep time SaO2 < 90%
Arousal index all
Age

Gender

Race

Income

<75
75-79
≥80

N (%)

<12,000
12,000 - <25,000
25,000 - <50,000
50,000 - 75,000
>75,000
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Severe
77.8 (4.9)
N=91
28.7
(5.5)
4.5 (11.7)
193.4(37.5)
129.4(28.4)
51.1 (12.3)
139.0(99.1)
14.0 (1.2)
4.1 (4.6)
79.4 (16.6)
13.3 (15.8)
36.5 (15.1)

F (P-value)
2.3 (0.1318)
F (P-value)
20.3
(<.0001)
2.5 (0.1159)
3.0 (0.0843)
0.4 (0.5504)
10.9 (0.0010)
0.11 (0.7401)
3.3 (0.0686)
0.2 (0.6381)
8.7 (0.0033)
79.7 (<.0001)
235.1(<.0001
)
X2 (P-value)
3.07 (0.8001)

Table 3: Characteristics of up to 1002 participants from the Cardiovascular Health Study
by severity of SDB (Continued)
Variable
Exercise Intensity
No Exercise
Low
Moderate
High

X2 (P-value)

N=162
7 (4.4)
57 (35.4)
71 (44.1)
26 (16.2)

N=91
7 (7.7)
34 (37.4)
39 (42.9)
11 (12.1)

X2 (P-value)

126 (35.8)
48 (13.6)
178 (50.6)

56 (34.6)
15 (9.3)
91 (56.2)

29 (31.9)
13 (14.3)
49 (53.9)

3.0 (0.8060)

19 (4.8)
123 (31.1)
194 (49.0)
56 (14.1)
4 (1.0

19 (5.4)
109 (31.0)
166 (47.3)
56 (16.0
1 (0.3)

3 (1.9)
62 (38.3)
71 (43.8)
23 (14.2)
3 (1.8)

3 (3.3)
21 (23.1)
46 (50.5)
18 (19.8)
3 (3.3)

17.6 (0.1279)

904
98

370 (93.4)
26 (6.6)

314 (89.0)
39 (11.0

141 (87.0)
21 (13.0)

79 (86.8)
12 (13.2)

8.3 (0.0395)

761
241

317 (80.0)
79 (20.0)

262 (74.2)
91 (25.8)

117 (72.2)
45 (27.8)

65 (71.4)
26 (28.6)

6.5 (0.0907)

934
68

375 (94.7)
21 (5.30)

327 (92.6)
26 (7.4)

153 (94.4)
9 (5.6)

79 (86.8)
12 (13.2)

7.8 (0.0493)

962
40

380 (96.0)
16 (4.0)

339 (96.0)
14 (4.0)

158 (97.5)
4 (2.5)

85 (93.4)
6 (6.6)

0.4592*

974
28

386 (97.5)
10 (2.5)

346 (98.0)
7 (2.0)

154 (95.1)
8 (4.9)

88 (96.7)
3 (3.3)

0.2724*

754
112
131

316 (80.2)
38 (9.6)
40 (10.2)

260 (74.1)
43 (12.2)
48 (13.7)

111 (68.9)
20 (12.4)
30 (18.6)

67 (73.6)
11 (12.1)
13 (14.3)

10.2 (0.1159)

Normal

Mild

71
388
393
143

N=396
25 (6.3)
149 (37.7)
161 (40.8)
60 (15.2)

N=353
32 (9.2)
148 (42.5)
122 (35.1)
46 (13.2)

Blood Pressure Status
Normal
Prehypertension
Hypertension

351
126
522

140 (35.5)
50 (12.7)
204 (51.8)

General Health Status
Excellent
Very Good
Good
Fair
Poor

44
315
477
153
11

MI Status
No
Yes
CHD
No
Yes
CHF
No
Yes
Stroke
No
Yes
Claudication
No
Yes
Diabetes Status (ADA)
Normal
IFG
Diabetic

AHI
Moderate

Severe

N

10.3 (0.3263)

Insomnia
No
797
310 (80.3) 275 (79.3)
133 (83.1)
79 (87.8)
Yes
186
76 (19.7)
72 (20.7)
27 (16.9)
11 (12.2)
4.0 (0.2643)
AHI CUTPOINTS (events/hr of sleep): Normal (<5); Mild (5 to <15); Moderate (15 to 30); Severe (>30)
*P-value from Fisher’s Exact Test.
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Table 4: Characteristics of up to 1002 participants from the Cardiovascular Health Study
by quartiles of CML
Variable
Age (years),
mean (s.d)
BMI (kg/m2)
Alcohol (GM)
Cholesterol (mg/dl)
Adjusted LDL (mg/dl)
HDL (mg/dl)
Triglyceride (mg/dl)
Hemoglobin (g/dl)
C-reactive protein (mg/L)
eGFR-cysC
% Sleep time of SaO2 < 90%
Arousal index all
Age

Quartile 1
76.3 (3.8)
N=251
28.5 (4.5)
5.5 (12.1)
205 (39.0)
129 (34.1)
52.1 (13.8)
157 (78.5)
14.0 (1.2)
4.6 (5.0)
84.9 (17.3)
4.7 (10.9)
21.9 (13.2)

CML
Quartile 2
Quartile 3
77.5 (4.4)
77.9 (4.5)
N=250
N=250
27.5 (4.5)
26.5 (4.2)
4.5 (8.5)
3.3 (8.4)
200 (35.6)
199 (37.4)
127 (33.0)
128 (31.8)
52.6 (13.5) 53.3 (14.4)
140 (74.6) 143 (103.0)
13.9 (1.4)
13.8 (1.2)
5.3 (10.9)
5.9 (12.9)
82.6 (17.9) 81.4 (18.5)
4.3 (11.2)
4.7 (12.5)
21.3 (11.2) 20.2 (10.2)

Quartile 4
78.4 (4.8)
N=251
26.4 (4.2)
4.0 (9.4)
200 (43.5)
128 (33.5)
55.7 (15.5)
136 (100.7)
13.5 (1.5)
4.2 (5.6)
80.5 (20.3)
3.7 (11.5)
20.1 (11.0)

F (P-value)
29.2(<.0001
F35.7(<.0001
(P-value)
)
4.6 (0.0327)
)
2.2 (0.1426)
0.12(0.7262)
8.0 (0.0047)
5.9 (0.0151)
19.3(<.0001
0.1 (0.8282)
)
7.0 (0.0081)
0.8 (0.3855)
4.0 (0.0473)
X2 (P-value)

263
455
284

84 (33.5)
121 (48.2)
46 (18.3)

62 (24.8)
118 (47.2)
70 (28.0)

62 (24.8)
109 (43.6)
79 (31.6)

55 (21.9)
107 (42.6)
89 (35.5)

Male
Female

429
573

96 (38.3)
155 (61.7)

113 (45.2)
137 (54.8)

115 (46.0)
135 (54.0)

105 (41.8)
146 (58.2)

3.9 (0.2776)

White
Black/AA
Other

816
179
7

209 (83.3)
41 (16.3)
1 (0.4)

199 (79.6)
49 (19.6)
2 (0.8)

208 (83.2)
39 (15.6)
3 (1.2)

200 (79.7)
50 (19.9)
1 (0.4)

0.6931*

BMI (kg/m2)
Normal
Overweight
Obese

311
464
215

42 (16.9)
139 (56.1)
67 (27.0)

76 (30.9)
111 (45.1)
59 (24.0)

97 (39.3)
105 (42.5)
45 (18.2)

96 (38.5)
109 (43.8)
44 (17.7)

Smoking Status
Non-smoker
Former smoker
Current smoker

485
449
63

110 (44.0)
116 (46.4)
24 (9.6)

104 (41.9)
128 (51.6)
16 (6.5)

134 (53.8)
98 (39.4)
17 (6.8)

137 (54.8)
107 (42.8)
6 (2.4)

21.7 (0.0014

168
333
293
89
66

49 (20.6)
84 (35.3)
70 (29.4)
23 (9.7)
12 (5.0)

40 (17.3)
73 (31.6)
77 (33.3)
22 (9.5)
19 (8.2)

34 (14.1)
94 (39.0)
75 (31.1 )
22 (9.1)
16 (6.6)

45 (18.8)
82 (34.3)
71 (29.7)
22 (9.2)
19 (8.0)

7.9 (0.7924)

Gender

Race

Income

<75
75-79
≥80

N (%)

N
1002
990
988
968
963
982
985
978
972
925
1002
959

<12,000
12,000 - <25,000
25,000 - <50,000
50,000 - 75,000
>75,000
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22.7(0.0009)

37.3(<.0001
)

Table 4: Characteristics of up to 1002 participants from the Cardiovascular Health Study
by quartiles of CML (cont’d)
N

Quartile 1

CML
Quartile 2
Quartile 3

Quartile 4

X2 (P-value)

71
388
393
143

N=251
24 (9.6)
94 (37.8)
98 (39.4)
33 (13.3

N=250
18 (7.3)
101 (40.9)
91 (36.8)
37 (15.0)

N=250
16 (6.4)
94 (37.8)
100 (40.2)
39 (15.6

N=251
13 (5.2)
99 (39.6)
104 (41.6)
34 (13.6)

X2 (P-value)

Blood Pressure Status
Normal
Prehypertension
Hypertension

351
126
522

88 (35.3)
38 (15.3)
123 (49.4)

97 (38.8)
30 (12.0)
123 (49.2)

88 (35.3)
31 (12.5)
130 (52.2)

78 (31.1)
27 (10.8)
146 (58.2)

6.8 (.3394)

General Health Status
Excellent
Very Good
Good
Fair
Poor

44
315
477
153
11

13 (5.2)
80 (31.9)
121 (48.2)
35 (13.9)
2 (0.8)

8 (3.2)
84 (33.7)
112 (45.0)
43 (17.3)
2 (0.8)

16 (6.4)
74 (29.7)
122 (49.0)
35 (14.1)
2 (0.8)

7 (2.8)
77 (30.7)
122 (48.6)
40 (15.9)
5 (2.0)

9.7 (0.6280)

904
98

225 (89.6)
26 (10.4)

227 (90.8)
23 (9.2)

229 (91.6)
21 (8.4)

223 (88.8)
28 (11.2)

1.3 (0.7367)

761
241

196 (78.1)
55 (21.9)

193 (77.2)
57 (22.8)

190 (76.0)
60 (24.0)

182 (72.5)
69 (27.5)

2.5 (0.4811

934
68

238 (94.8)
13 (5.2)

235 (94.0)
15 (6.0)

231 (92.4)
19 (7.6)

230 (91.6)
21 (8.4)

2.5 (0.4714)

962
40

244 (97.2)
7 (2.8)

238 (95.2)
12 (4.8)

239 (95.6)
11 (4.4)

241 (96.0)
10 (4.0)

1.5 (0.6863)

974
28

243 (96.8)
8 (3.2)

244 (97.6)
6 (2.4)

247 (98.8)
3 (1.2)

240 (95.6)
11 (4.4)

5.0 (0.1751)

754
112
131

174 (69.3)
34 (13.6)
43 (17.1)

183 (73.5)
32 (12.9)
34 (13.7)

197 (79.8)
25 (10.1)
25 (10.1)

200 (80.0)
21 (8.4)
29 (11.6)

11.7(0.0678)

Variable
Exercise Intensity
No Exercise
Low
Moderate
High

MI Status
No
Yes
CHD
No
Yes
CHF
No
Yes
Stroke
No
Yes
Claudication
No
Yes
Diabetes status (ADA)
Normal
IFG
Diabetic

5.6 (0.7836)

Insomnia
No
797
194 (79.8)
194 (79.5)
201 (81.7)
208 (83.2)
Yes
186
49 (20.2)
50 (20.5)
45 (18.3)
42 (16.8)
1.4 (0.6976)
LOG(CML) Quartiles (ng/ml): (1) ≤6.1972; (2) >6.1972-6.3599; (3) 6.3599-6.5341; (4) >6.5341
*P-value from Fisher’s Exact Test;
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Table 5: The effect of SDB (AHI) on CML (N=1002)
Parameter
AHI (events/hr):
Model 1AHI (events/hr):
Model 2
SDB Severity: Model 1
Normal
Mild
Moderate
Severe
SDB Severity: Model 2
Normal
Mild
Moderate
Severe

N

Estimate
-0.0003
-0.0004

Standard Error
0.0007
0.0008

t Value
-0.32
-0.56

Pr >|t|
0.7218
0.5770

396
353
162
91

Referent
0.0209
0.0040
0.0089

0.0205
0.0260
0.0325

1.02
0.15
0.27

0.3080
0.8769
0.7842

396
353
162
91

Referent
0.0314
0.0040
0.0004

0.0214
0.0275
0.0348

1.47
0.15
0.01

0.1425
0.8842
0.9915

Model 1 was unadjusted; Model 2 adjusted for age, gender, BMI, smoking, alcohol, HDL, C-reactive
protein, hemoglobin, eGFR-Cystatin C, CHD, MI, Claudication, Stroke, diabetes, hypertension, race.

Table 6: Interaction checks and model selection
Model # Model
DF
LR
1
Main Effects (No interaction)
24
319.4
2
A*H
27
333.1
3
A*G
27
327.1
4
H*G
25
324.9
5
(A*H) (A*G)
28
339.2
6
(A*H) (A*G) (H*G)
29
344.6
7
(A*H) (A*G) (H*G) (A*H*G) 32
354.2
A=Apnea-Hypopnea Index; H=Hemoglobin; G=Gender

46

P-value
0.0033
0.0526
0.0190
0.0135
0.0201
0.0223

Comments
b/n model 2 & 1
b/n 3 & 1
b/n 4 & 1
b/n 5 & 2
b/n 6 & 5
b/n 7 & 6

Table 7: The effect of SDB (AHI) on CML stratified by GENDER and HEMOGLOBIN
concentration

N

<13.20
β
P-value

HEMOGLOBIN
13.20 – 14.29
N
β
P-value

N

>14.29
β
P-value

ALL (N=978)
SDB Severity:
Normal (n=389)
Mild (n=340)
Moderate(n=158)
Severe (n=91)

138
111
43
24

Ref
0.049
0.021
0.054

0.261
0.723
0.484

132
124
58
31

Ref
0.037
0.033
0.026

0.220
0.387
0.619

119
105
57
36

Ref
0.016
-0.039
-0.062

0.676
0.401
0.271

MALES (N=423)
SDB Severity:
Normal (n=129)
Mild (n=154)
Moderate (n=83)
Severe (n=57)

23
19
8
8

Ref
-0.082
-0.075
0.010

0.588
0.679
0.962

40
51
31
18

Ref
0.068
0.104
0.038

0.166
0.086
0.606

66
84
44
31

Ref
-0.067
-0.084
-0.161

0.166
0.152
0.0146

FEMALES (N=555)
SDB Severity:
Normal (n=260)
115
Ref
92
Ref
53
Ref
Mild (n=186)
92
0.055
0.249
73
0.041
0.328
21
0.189
0.0061
Moderate (n=75)
35
0.023
0.729
27
-0.009
0.864
13
0.050
0.553
Severe (n=34)
16
0.063
0.480
13
-0.013
0.877
5
0.281
0.0336
Models were adjusted for age, BMI, smoking, alcohol, HDL, C-reactive protein, eGFR-Cystatin C, CHD,
MI, Claudication, Stroke, diabetes, hypertension, race.
Ref=Referent
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Table 8: The effect of SDB (AHI) on CML by HEMOGLOBIN concentration
Parameter

N

HEMOGLOBIN CLASS 1 (<12.7 g/dl)
SDB Severity:
Normal
Mild
Moderate
Severe

185

HEMOGLOBIN CLASS 2 (12.7 – 14.59)
SDB Severity:
Normal
Mild
Moderate
Severe

552

Estimate

Standard Error

t Value

Referent
0.029
0.009
0.019

0.058
0.076
0.108

0.51
0.12
0.18

0.614
0.903
0.858

Referent
0.0591
0.030
0.0909

0.026
0.034
0.042

2.29
0.89
2.15

0.0223
0.376
0.0318

78
67
28
12

221
195
83
53

Pr >|t|

HEMOGLOBIN CLASS 3 (≥14.6 g/dl)
241
SDB Severity:
Normal
90
Referent
Mild
78
-0.025
0.043
-0.57
0.569
Moderate
47
-0.039
0.053
-0.74
0.458
Severe
26
0.065
-2.11
-0.1381
0.0364
Models were adjusted for age, BMI, gender, smoking, alcohol, HDL, C-reactive protein, eGFR-Cystatin C,
CHD, MI, Claudication, Stroke, diabetes, hypertension, race.
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CHAPTER THREE
THE JOINT EFFECT OF OBESITY AND SLEEP INADEQUACY ON RISK OF
TYPE-2 DIABETES

3.1 INTRODUCTION
Diabetes is the seventh leading cause of death in the US affecting 25.8 million
people (8.3% of the U.S population)128 . It is a major risk factor for hypertension, heart
disease and stroke. Co-morbid effects of diabetes include kidney disease, blindness,
nervous system damage, and too commonly nontraumatic lower-limb amputation.
Several epidemiological studies have indicated an association between poor patterns of
sleep and diabetes risk but the results have not been conclusive129-134. Moreover, sleep
duration and sleep quality have often been analyzed separately in both longitudinal and
cross-sectional studies, and only very few studies have incorporated aspects of both sleep
duration and quality into their analyses135, 136. Sleep duration is measured by the number
of hours a person sleeps in a day, and does not take into account the nature of the sleep.
Sleep quality on the other hand describes the total sleep pattern of an individual. Major
factors deleterious to sleep quality include sleep apnea, anxiety (depression), insomnia,
snoring, and medical conditions such as COPD, heartburn, lung problems, chronic pain,
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and enlarged prostate137-140. These factors can lead to difficulty either in initiating sleep
or in maintaining sleep141, 142.
Obesity plays an important role in the association between sleep and diabetes.
Obesity prevalence is known to be higher among those with short sleep duration143-146,
and obesity is also known to elevate the risk of diabetes147, 148. Sleep problems such as
obstructive sleep apnea (OSA) and snoring have also been found to increase the risk of
diabetes independent of obesity149, making it unclear what role obesity plays in the
association between sleep and diabetes. Previous studies have generally adjusted for
obesity or BMI but have not specifically investigated the potential complex role obesity
plays in the relationship between sleep insufficiency and diabetes129, 134, 150. It is possible
that associations between sleep and diabetes are modified or confounded by obesity.
Furthermore, sleep disorders, obesity, and diabetes are all entangled in web of
oxidative stress. It is however not clear whether it is the oxidative stress from sleepdisordered breathing that contributes to the development of diabetes, or if sleep problems
are the results of diabetes. The association gets even more complicated in the presence of
obesity. This study investigates the joint effect of sleep and obesity on the risk of diabetes
with the aim of identifying relationships that may be useful in explaining some of the
complication and provide basis for sound public health practice.
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3.1.1 Objectives
1. To investigate the association between sleep and diabetes using sleep quantity and
quality measures
2. To investigate the effect of possible interaction between sleep quantity and sleep
quality on the diabetes
3. To investigate the joint effect of sleep and obesity on the risk of diabetes

3.1.2 Hypothesis
We hypothesize that sleep quantity and sleep quality are independently associated with
the risk of diabetes and their interaction with obesity exacerbates the risk.

3.1.3 Justification
Sleep duration among Americans has been decreasing since the industrial
revolution. Type-2 diabetes, a major risk factor for cardiovascular disease (CVD), has
also been on the rise during the same period. Obesity, a risk factor for type-2 diabetes and
CVD, has now reached epidemic level in the United States raising health concerns for
this and future generations. Apart from physical activity and dietary recommendations
which are yet to have full impacts, the search for opportunities to reduce type-diabetes
and CVD is an ongoing process. Understanding the relationship between sleep problems
and type-2 diabetes and how obesity changes the dynamics could fill the gaps in
knowledge of type-2 diabetes and move us closer to ensuring a healthy nation.
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3.2.0 METHODS
3.2.1 Study Design: Prospective cohort study of the First National Health and Nutrition
Examination Survey (NHANES 1).
3.2.2 Study Participants: Participants were selected from the Epidemiologic Follow-up
Study of the First National Health and Nutrition Examination Survey (NHANES 1)
between 1982 and 1992. NHANES is a survey designed to assess the health and
nutritional status of the non-institutionalized population of the United States151. There
were a total of 12,220 records at baseline (1982-1984) which indicated a response to at
least one of the questions on sleep quality or quantity. However, among these 12,220
records are included some responses collected by proxy for individuals deceased between
1982 and 1984, and since this is a longitudinal study, only participants who were alive at
baseline (n=10,523) were included. Further exclusions include participants who were
diabetic at baseline (n=888). This resulted in sample size of 9635.

3.2.3 Exposure Assessment
The following questions were used to assess sleep quality: “(1) how often do you
have trouble falling asleep? (2) how often do you have trouble with waking up during the
night? (3) how often do you have trouble waking up too early and not being able to fall
asleep? (4) how often do you get so sleepy during the day or evening that you have to
take a nap?”. Responses to each of these questions were based on a 5-point scale
(“Never”, “Rarely”, “Sometimes”, “Often”, and “Almost always”). These responses were
summed up across the 4 sleep problem items to form the sleep quality variable. Our
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preliminary analyses did not show significant differences between responses “Never” and
“Rarely” and diabetes and between “Often”, and “Almost always” and diabetes. Hence to
ensure adequate sample size in our response categories for valid results these categories
were combined. The resulting sleep quality classes are: (1) “good sleep” (subjects who
“never” or “rarely” have sleep problems); (2) “moderate sleep” (subjects who
“sometimes” have sleep problems); (3) “poor sleep” (subjects who “often”, or “almost
always” have sleep problems). A sleep quantity indicator was created based on a single
question, “how many hours of sleep do you usually get per night?” The sleep quantity
indicator was categorized as <7 hours of sleep, 7 to 9 hours of sleep, and >9 hours of
sleep.

3.2.4 Diabetes Assessment
Incidence of diabetes from baseline (1982-1984) to 1992 was ascertained from
self-reports by subjects (physician diagnosed), and from primary recorded cause of death
(ICD-9: 250-250.93) for those who were deceased during follow-up, but did not report a
diagnosis of diabetes prior to death.

3.2.5 Assessment of Covariates
Age of subjects at baseline was categorized into 4 groups (<45, 45-54, 55-68, and
>68). The cut-points were set to ensure an adequate number of subjects in all classes, and
to take into account the effect of age on both sleep and diabetes. Race/ethnicity was
categorized as “white”, “black” or “other”, where “other” includes Asian or Pacific
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Islanders, American Indians, and Eskimos. BMI was categorized as “normal” (<25.0),
“overweight” (25-29.9), and “obese” (≥30). Blood pressure was categorized as “normal”,
“prehypertension”, and “hypertension” according to the Seventh report of the Joint
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood
Pressure (JNC VII) criteria 152. Self-reported cigarette smoking was classified as “never
smoker”, “former smoker”, and “current smoker”, while self-reported alcohol
consumption was classified as “abstainer”, “light drinker”, “moderate drinker”, and
“heavy drinker”. Self-reported physical activity was classified as “very active”,
“moderately active”, and “quite Inactive”, and educational status will be categorized as
“<high school”, “high school”, and “> high school”. Self-reported coffee drinking and
depression were assessed as “yes or no”.

3.2.6 Statistical Analyses
Chi-square tests were used to test whether categorical variables differed across the
levels of sleep quantity and quality. Associations between continuous covariates with
sleep quantity and quality were estimated using analysis of covariance. Lastly, Cox
proportional hazards models were used to estimate the association between sleep quantity
and sleep quality and time to onset of diabetes in the study sample. Various models were
constructed: Model 1 was unadjusted, Model 2 adjusted for age, and Model 3 adjusted for
Age, BMI, Sex, Race, Hypertension, Cigarette Smoking, Alcohol Consumption,
Depression, Coffee Drinking, Physical Activity, and Education. Model variables were
selected because they are known to influence both sleep and diabetes. A final model
included an interaction term for BMI and sleep (quantity and quantity). A likelihood ratio
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test was used to check for possible interaction between BMI and sleep. A significance
level of 0.05 was used to determine all significant associations. All analyses were
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).

3.2.7 Power Calculation (Sleep Inadequacy and Type-2 Diabetes)
3.2.8 Prevalence of sleep problems in the U.S population
An estimated 70 million Americans suffer sleep problems (that is, about 23% of
the U.S population by 2010 census)153. This include sleep restriction, primary sleep
disorders (various forms of sleep disorders affecting people of all ages) , and secondary
sleep disorders (common in people with a chronic disease, or an alcohol or substance
abuse disorder, accompanied with poor sleep quality and excessive daytime sleepiness).
Of 9284 subjects who self-reported their sleep quality, 39.9% of them reported poor sleep
quality. This gives an exposed group of 3640 and unexposed group of 5644 in terms of
sleep quality.
3.2.9 Prevalence of type-2 diabetes among exposed and unexposed groups
11.3% of Americans ≥20 years have diabetes154. In this study however, the
proportion of subjects with poor sleep quality who are diabetic is 6.3%, and the
proportion of subjects with good or moderate sleep who are diabetic is 4.1%. Assuming
95% confidence level, the power of the study is more than 80% as shown in table 9.
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Table 9: Power calculation for the association between sleep inadequacy and type-2diabetes
Power for Cohort Studies (Sleep Inadequacy and Type-2-Diabetes)
Exposed Group
Unexposed Group
Sample Size

3640

5644

6.3

4.1

Prevalence (or) Coverage (%)
Power based on:
Normal approximation

99.75%

Normal approximation with continuity
correction

99.71%

3.3 RESULTS
Over the 10 year follow-up period, there were 465 incident cases of diabetes
(4.8%). The mean age and BMI of study subjects were 56 years and 26.0, respectively.
Females formed 62.8% of the study sample and most of the subjects were white (86.8%).
53.8% of the subjects were either overweight or obese and 71.1% were either
prehypertensive or hypertensive. Current cigarette smokers form 28.4% of the sample
and moderate to heavy drinkers form 11.6%. The study sample was also characterized by
high school education or more (63.1%), and physically very active individuals form
28.2%. Subjects who had an income of $25,000 or more form 36.9% of the sample,
coffee drinkers 86.2%, and depressed subjects 2.5%.
Covariates more likely to lead to poor sleep quality were increasing age,
overweight/obesity, white race, female sex, high blood pressure, depression, less than
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$25,000 of income, physical inactivity, and less than high school educational status. On
the other hand, current cigarette smoking and light to moderate alcohol consumption
appear to promote good sleep quality [Table 10]. Sleep quality and quantity were treated
in this study as independent predictors of diabetes because a test of interaction between
them did not reach statistical significance (p=0.3751). Results from the Cox proportional
hazards model showed that poor sleep quality was significantly associated with diabetes
in the unadjusted model (HR=1.63, 95%CI=1.26-2.10). The association remained
significant in the age-adjusted (HR=1.36, 95% CI=1.04-1.76) and multivariable adjusted
(HR=1.47, 95%CI=1.09-1.99) models. Compared with 7 to 9 hours of sleep, subjects
who slept for less than 7 hours and those who slept for more than 9 hours are
significantly at risk of diabetes in unadjusted and age adjusted models. The association
however did not reach statistical significance when all relevant covariates were adjusted
for [Table 12].
A joint effect of BMI and sleep quantity on diabetes was considered but was not
significant (p=0.5879). A significant interaction effect between BMI and sleep quality on
diabetes however was found (p=0.0151). It was found that obese subjects who have poor
sleep quality were at a much greater risk of diabetes compared to those with normal BMI
and good sleep patterns (HR=31.11, 95%CI=11.37 – 85.17) after adjusting for age, sex,
race, hypertension, cigarette smoking, alcohol consumption, depression, coffee drinking,
physical activity, educational status, and sleep quantity [Table 13]. In order to find
absolute risk estimates for the effect of sleep quality on diabetes, 1 unit change in sleep
quality was evaluated within each category of BMI. Within the obese BMI category 1
unit change in sleep quality was associated with 1.270 (1.037-1.556) risk of diabetes; 1
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unit change in sleep quality does not appear to have an effect on diabetes among
overweight subjects (HR=0.996; 95%CI=0.795-1.248); and within the normal BMI
category, 1 unit change in sleep quality was associated with 1.557 (1.107 – 2.191) risk of
diabetes [Table 14].

3.4 DISCUSSION
Previous investigations of the effect of sleep duration on diabetes risk have found
U-shaped relationships; with too little or too much sleep leading to an increased risk of
diabetes. The mechanisms by which sleep deprivation could contribute to diabetes have
been established but little is known about how excess sleep could increase the risk of
diabetes. Possible explanations for the association between excess sleep and diabetes
include: (1) other medical conditions associated with diabetes resulting in longer time in
bed, or (2) less physical activity due to more time spent in bed. The effect of sleep
quantity on diabetes has demonstrated this U-shaped relationship with <7 hours and >9
hours of sleep having higher risk estimates compared to the reference group 7-9 hours of
sleep [Table 12]. In our multivariable model without considering interactions, we found
elevated risks for diabetes for both short (HR=1.06; 95% CI=0.85-1.32) and long sleep
(HR=1.46; 95%CI=0.93-2.30) when compared with the referent (7-9 hours), although
these were not significant after adjusting for confounding factors [Table 12].
Gangwisch et al129 found an odds ratio of 1.47 (1.03-2.09) for the effect of sleep
duration of ≤ 5 hours on diabetes, and 1.52 (1.06-2.17) for the effect of ≥9 hours of sleep
on diabetes, with 7 hours of sleep as the reference group. The main difference between
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the effect estimates of sleep duration from this study and that of Gangwisch et al., is that
whilst Gangwisch et al., made 7 hours as their reference group and estimated risks for ≤
5, 6, 8, and ≥9 hours of sleep, this study estimated the effects for <7 and >9 hours of
sleep with 7-9 hours of sleep as referent. This was done to conform to recommendations
by the National Sleep Foundation (NSF) that adults need 7-9 hours of sleep per night for
proper functioning. Therefore estimating risk for sleep quantity below and above the
recommended amount could be easily interpreted within the guidelines of the NSF.
Rafalson et al.,155 in a nested case-control study, found a threefold increased risk of
diabetes (OR=3.0; 95%CI=1.05 - 8.59) for sleep duration <6.0 hrs compared to 6 to 8 hrs.
As already explained, the difference in estimates may be due to differences in the sleep
duration classifications adopted. Longitudinal studies by Yaggi et al.,132, Ayas et al.,156
and Tuomilehto et al.,157 did not find significant associations between short sleep duration
and diabetes. Since ours was also a longitudinal analysis, it raises questions as to which
study design best estimates the effect of sleep duration on diabetes.
Longitudinal studies on sleep quality and diabetes have received much attention
because many of them found significant risk estimates. Kawakami et al.,158 found a
threefold increased risk of diabetes (HR=2.98; 95%CI=1.36 – 6.53) among subjects who
have “high” compared to “low” difficulty initiating sleep. They also found that “high”
difficulty maintaining sleep doubles the risk of diabetes compared to “low” (HR=2.23;
95%CI=1.08 – 4.61). In our fully adjusted model, poor sleep quality significantly
increased the risk of diabetes (HR=1.47; 95%CI=1.09-1.99). Our effect estimate was
different than those reported by Kawakami et al., and may be due to the fact that they
studied only males and did not adjust for number of hours of sleep. Moreover, our sleep
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quality variable was formed from four different questionnaire items whilst estimates by
Kawakami et al., were based on either difficulty initiating sleep or difficulty maintaining
sleep. Meisinger et al.,133 also found “difficulty maintaining sleep” to be significantly
associated with diabetes (Males: HR=1.60, 95%CI=1.05 – 2.45; Females: HR=1.98, 95%
CI=1.20 – 3.29). Meisinger et al., did not consider duration of sleep and males and
females were analyzed separately, making their estimates to be slightly different from
what we observed.
Sleep quality issues can be attributed to many factors including but not limited to
depression, excessive alcohol consumption, physical inactivity, and sleep apnea. These
factors could independently or in combination disrupt sleep and contribute to diabetes.
Longitudinal studies by Marshall et al.,150 Botros et al.,130 and Celen et al.,131 have all
found significant associations between obstructive sleep apnea and diabetes while AlDelaimy et al.,159 found that occasional and regular snoring increased the risk of diabetes.
Our estimate is similar to those of Botros et al., (HR= 1.43, 95%CI: 1.10-1.86) and AlDelaimy et al., (occasional snoring: RR=1.41, 95% CI: 1.22 - 1.63; regular snoring
RR=2.03, 95%CI: 1.71 - 2.40), but very different from those by Marshall et al.,
(moderate- to- severe OSA: OR= 13.45, 95% CI=1.59 - 114.11) and Celen et al., (OSA in
women; OR=11.78, 95%CI: 1.14-121.7). Marshall et al., had only 9 incident diabetes
cases out of 295 subjects over a 4 year period which explains their wide confidence
interval, and Celen et al., had only 31 women involved in their study out of which 7 had
diabetes during follow-up leading to a wide confidence interval as well. The
longitudinal study by Bjorkelund et al.,135 combined some components of sleep duration
and quality. Their risk estimate however was insignificant although similar to ours in
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magnitude (HR=1.35; 95%CI= 0.89 – 2.10). Bjorkelund et al., combined three items (1)
sleep complaints, (2) use of sleeping pills, and (3) sleep <6h in 24hrs, and categorized the
composite sleep problem variable as “yes” or “no”. This dichotomization may cause loss
of vital information rendering the statistical test insignificant.
While risk estimates from longitudinal studies remain conflicting, those from
cross-sectional studies have been consistent. Cross-sectional studies by Kachi et al.,160,
Lou et al.,161, Chao et al.,162, Hsieh et al.,163, Tuomilehto et al.,164, Chaput et al.,165, and
Gottlieb et al.,166 have all found significant associations between short sleep duration and
risk of diabetes. Cross-sectional studies measure both exposure and outcome at the same
time and it may be possible that the short sleep duration was as a result of some other
health condition or even as a result of diabetes. In addition, these studies estimated only
the effect of short sleep duration on diabetes without considering the effect of sleep
quality. In contrast, the cross-sectional study by Jongoh Kim et al.,167 did not find any
association between sleep duration and diabetes in the entire study sample of 1,652
Korean men. However, after stratification by abdominal obesity, they did find an
increased risk of diabetes among 1,241 of the men without abdominal obesity and who
sleep duration of ≤5 hours per day. We did not find significant association between sleep
duration and diabetes and we did not perform stratified analyses of sleep duration by BMI
because our test for interaction between sleep duration and BMI was not significant.
However, the pattern is similar if short sleep duration is taken to be a proxy for poor sleep
quality.
Cross-sectional studies by Ronksley et al., 168 and Reichmuth et al.,169 found that
sleep apnea significantly increased the risk of diabetes in both males and females. This is
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consistent with findings from our longitudinal analysis that poor sleep quality
significantly increased the risk of diabetes. The cross-sectional study by Vgontzas et
al.,136 did not find individual associations between insomnia and diabetes, or sleep
duration and diabetes, but after examining the joint effects of insomnia and sleep
duration, they found that compared to normal sleeping subjects (sleep duration of >6
hours), those with insomnia and with short sleep duration (<5 hours) were at increased
risk of diabetes. Our sleep quality variable was composed of items other than insomnia
and although we did not stratify on number of hours of sleep, we found a significant
relationship between poor sleep quality and diabetes after adjusting for confounders
including sleep duration. Mahmood et al.,134 however did not find significant association
between obstructive sleep apnea and diabetes after adjusting for confounding variables.
The study by Mahmood et al., was predominantly African Americans (67%), whereas our
study was predominantly Caucasian (87%). This vast difference in ethnicity between the
two studies could be a reason for differences in effect estimates. Most of the crosssectional associations have been consistent but they cannot show a causal direction. We
have found in our prospective study a risk estimate of 1.47 for the effect of poor sleep
quality on diabetes risk, and it is statistically significant.
Obesity is a known risk factor for diabetes, but the effect of its interaction with
sleep on diabetes as reported here has not been specifically investigated and reported. We
found 31 fold increased risk of diabetes among obese subjects with poor sleep quality
when compared to normal weight subjects with good sleep quality [Table 13]. The hazard
ratio for the effect of poor sleep quality on diabetes was only 1.47 [Table 12] when BMI
served as confounder. Effect sizes of around 1.47 have been common because researchers
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often treat BMI as a confounding variable which makes it impossible for the full public
health impact of sleep and obesity on diabetes to be assessed. Poor sleep quality could
cause changes in appetite regulating hormones, leptin and ghrelin, which may lead to
weight gain and obesity, and subsequently diabetes148. Other mechanisms by which poor
quality sleep increases diabetes risk include overactivity of the sympathetic nervous
system, increased inflammation, elevated evening cortisol levels, all of which leads to
reduced insulin sensitivity and diabetes. Poor sleep has also been proposed to result in
reduced energy expenditure which could also affect weight status and ultimately diabetes
149

. Among normal BMI subjects 1 unit change in sleep quality (good-moderate-poor)

was associated with 1.557 (1.107-2.191) risk of diabetes. Among obese subjects 1 unit
change in sleep quality was associated with 1.270 (1.037-1.556) risk of diabetes. Sleep
quality did not appear to influence the risk of diabetes among overweight subjects [Table
14]. In other words overweight subjects have a baseline risk of diabetes which is higher
than that of normal weight subjects [Table 13] but once that point is reached then the
effect of sleep does not seem to matter.
We were able to show in this study that sleep duration and sleep quality have
independent influences on diabetes risk. Furthermore, we found that BMI modify the
effect on sleep quality on diabetes. The prospective nature of the study also enhances our
analysis because we could establish temporality. Only subjects who were alive at the start
of the study were included to eliminate errors that arise from proxy responses. Our study
has limitations as well. All the information provided in this document on sleep was selfreported by subjects and could potentially bias the findings; a sleep study on the subjects
can solve this problem. However it has been shown that the use of self-reported sleep,
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characterized by the dimensions used in this study, provides just as good a measure as
when monitored 170. Also, only a single record of sleep documented at baseline (19821984) was used, instead of multiple records. Sleep habits may change over time and
cause misclassification of subjects on the exposure. However, it is not likely these
misclassifications would change findings significantly because they would be nondifferential.

3.5 CONCLUSION
Poor sleep quality has been found to significantly increase the risk of diabetes in
the NHANES 1 Epidemiologic Follow-up Study. When the joint effect of obesity was
considered, the effect of sleep quality on diabetes was found to be exacerbated among
normal weight subjects. Obese subjects already have higher baseline risk of type-2diabetes and although sleep quality does matter, the difference was not as large as found
among normal weight subjects. Sleep cycles influence hormone levels, such as cortisol
and growth hormone, as well as inflammation processes evidenced by effects on markers
of inflammation, such as TNF-α and IL-6. Therefore, poor quality sleep could disrupt
hormone and inflammation responses, so that poor sleep over time may lead to impaired
glucose tolerance and diabetes. Poor sleep patterns also influences energy expenditure, in
part through the disruption of hunger suppressing and stimulating hormones which are
also thought to be contributing factors to obesity and hence diabetes. The risk estimates
of interaction between poor sleep quality and BMI found in this study warrants some
attention. Thus, we recommend weight management efforts to be intensified and sleep
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problems reduced with every available resource in order to reduce the incidence of
diabetes. Additional studies are needed to examine the effect of sleep on diabetes risk
among overweight individuals and to explain possible biologic mechanisms why sleep
quality may not be an important risk factor for diabetes among overweight individuals.

65

Table 10: Baseline Characteristics by sleep quality
Sleep Quality
Moderate
Poor
N=3464
N=3640

Baseline Characteristics

N

Good
N=2180

Age, y: Mean (SD)
BMI: Mean (SD)

9284
9129

51.0 (13.3)
26.0 (4.8)

54.2 (14.0)
26.0 (4.8)

60.9 (14.6)
26.1 (4.9)

Age Category, n(%)
<45
45-54
55-68
>68

2579
2213
2194
2298

887 (34.4)
564 (25.5)
430 (19.6)
299 (13.0)

1085 (42.1)
881 (39.8)
828 (37.7)
670 (29.2)

607 (23.5)
768 (34.7)
936 (42.7)
1329 (57.8)

BMI Category, n(%)
<25.0
25-29.9
>29.9

4217
3270
1642

1020 (24.2)
771 (23.6)
366 (22.3)

1617 (38.3)
1193 (36.5)
600 (36.5)

1580 (37.5)
1306 (39.9)
676 (41.2)

9.13 (0.0580)

White
Black
Other

8063
1132
89

1811 (22.5)
345 (30.5)
24 (27.0)

3021 (37.5)
402 (35.5)
41 (46.1)

3231 (40.1)
385 (34.0)
24 (27.0)

43.23 (<.0001)

Male
Female

3457
5827

939 (27.2)
1241 (21.3)

1252 (36.2)
2212 (38.0)

1266 (36.6)
2374 (40.7)

42.95 (<.0001)

HYPERTENSION
Normal
Prehypertensive
Hypertensive

2601
3645
2756

744 (28.6)
836 (22.9)
552 (20.0)

1038 (39.9)
1365 (37.5)
971 (35.2)

819 (31.5)
1444 (39.6)
1233 (44.7)

112.26 (<.0001

SMOKING
Never
Former
Current

4183
2464
2636

950 (22.7)
545 (22.1)
685 (26.0)

1567 (37.5)
884 (35.9)
1013 (38.4)

1666 (39.8)
1035 (42.0)
938 (35.6)

26.47 (<.0001)

ALCOHOL
Abstainer
Light Drinker
Moderate Drinker
Heavy Drinker

3902
4282
999
76

827 (21.2)
1077 (25.2)
251 (25.1)
18 (23.7)

1382 (35.4)
1647 (38.5)
403 (40.3)
25 (32.9)

1693 (43.4)
1558 (36.4)
345 (34.5)
33 (43.4)

55.07 (<.0001)

2601
5148
1488

773 (29.7)
1135 (22.1)
264 (17.7)

979 (37.6)
2023 (39.3)
449 (30.2)

849 (32.6)
1990 (38.7)
775 (52.1)

186.27 (<.0001

7998
1276

1865 (23.3)
314 (24.6)

2961 (37.0)
499 (39.1)

3172 (39.7)
463 (36.3)

5.26 (0.0721)

RACE

SEX

PHYSICAL ACTIVITY
Very Active
Moderately Active
Quite Inactive
COFFEE
Yes
No

66

F (P-value)
743.04 (<.0001
1.51 (0.2195)
X2(P-value)

699.36(<.0001)

Table 10: Baseline Characteristics by sleep quality (Continued)
Baseline Characteristics

N

Sleep Quality
Good
Moderate
N=2180
N=3464

DEPRESSION
Yes
No

229
8973

26 (11.4)
2138 (23.8)

62 (27.1)
3369 (37.6)

141 (61.6)
3466 (38.6)

INCOME, $
<10000
10,000-24,999
25,000-49,000
>50,000

2389
3036
2374
805

369 (15.5)
733 (24.1)
699 (29.4)
250 (31.1)

810 (33.9)
1088 (35.8)
982 (41.4)
323 (40.1)

1210 (50.6)
1215 (40.0)
693 (29.2)
232 (28.8)

EDUCATION
<HS
HS
>HS

3404
3456
2372

653 (19.2)
862 (24.9)
656 (27.7)

1147 (33.7)
1352 (39.1)
945 (39.8)

1604 (47.1)
1242 (35.9)
771 (32.5)

DIABETES
Yes
No

447
8837

82 (18.3)
2098 (23.7)

150 (33.6)
3314 (37.5)

215 (48.1)
3425 (38.8)

SLEEP QUANTITY (hrs)
<7
7-9
>9

6095
2599
293

1592 (26.1)
453 (17.4)
63 (21.5)

2545 (41.8)
729 (28.1)
91 (31.1)

1958 (32.1)
1417 (54.5)
139 (47.4)
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Poor
N=3640

X2 (P-value)

51.33
(<.0001)

305.14
(<.0001

157.52
(<.0001
16.52
(0.0003)

393.0
(<.0001)

Table 11: Baseline characteristics by sleep quantity
Baseline Characteristics
Age, y: Mean (SD)
BMI: Mean (SD)

Sleep Quantity (hrs)
7-9
N=6096

N

<7
N=2599

8988
8842

56.0 (14.5)
26.5 (5.0)

55.6 (14.5)
25.9 (4.8)

>9
N=293

F (P-value)

66.7 (15.0)
26.1 (5.1)

64.94 (<.0001)
22.45 (<.0001)
X2(P-value)

Age Category, n(%)
<45
45-54
55-68
>68

2491
2149
2118
2230

699 (28.1)
699 (31.1)
598 (28.2)
633 (28.4)

1756 (70.5)
1447 (67.3)
1456 (68.8)
1437 (64.4)

36 (1.4)
33 (1.6)
64 (3.0)
160 (7.2)

BMI Category, n(%)
<25.0
25-29.9
>29.9

4092
3158
1592

1084 (26.5)
942 (29.8)
528 (33.2)

2884 (70.5)
2114 (67.0)
1013 (63.6)

124 (3.0)
102 (3.2
51 (3.2)

28.14 (<.0001)

White
Black
Other

7834
1067
87

2181 (27.8)
383 (35.8)
36 (41.4)

5421 (69.2)
624 (58.5)
51 (58.6)

232 (3.0)
61 (5.7)
-

67.04 (<.0001)

Male
Female

3334
5654

972 (29.1)
1627 (28.8)

2237 (67.1)
3859 (68.2)

125 (3.8)
168 (3.0)

4.41 (0.1102)

HYPERTENSION
Normal
Prehypertensive
Hypertensive

2527
3535
2666

637 (25.2)
1068 (30.2)
811 (30.4)

1834 (72.6)
2366 (66.9)
1735 (65.1)

56 (2.2)
101 (2.9)
120 (4.5)

51.13 (<.0001)

SMOKING
Never
Former
Current

4067
2377
2543

1093 (26.9)
697 (29.3)
809 (31.8)

2823 (69.4)
1606 (67.6)
1666 (65.5)

151 (3.7)
74 (3.1)
68 (2.7)

22.31 (0.0002)

ALCOHOL
Abstainer
Light Drinker
Moderate Drinker
Heavy Drinker

3814
4122
954
75

1074 (28.2)
1207 (29.3)
283 (29.7)
31 (41.3)

2565 (67.2)
2822 (68.4)
650 (68.1)
42 (56.0)

175 (4.6)
93 (2.3)
21 (2.2)
2 (2.7)

44.0 (<.0001)

2517
4991
1440

765 (30.4)
1365 (27.4)
461 (32.0)

1694 (67.3)
3480 (69.7)
898 (62.4)

58 (2.3)
146 (2.9)
81 (5.6)

54.09 (<.0001)

7750
1229

2247 (29.0)
349 (28.4)

5269 (68.0)
821 (66.8)

234 (3.0)
59 (4.8)

10.66 (0.0048)

RACE

SEX

PHYSICAL ACTIVITY
Very Active
Moderately Active
Quite Inactive
COFFEE
Yes
No

68

161.54
(<.0001

Table 11: Baseline Characteristics by sleep quantity (Continued)
N

1
N=2599

DEPRESSION
Yes
No

222
8687

83 (37.4)
2497 (28.7)

INCOME, $
<10000
10,000-24,999
25,000-49,000
>50,000

2332
2926
2310
773

EDUCATION
<HS
HS
>HS

Sleep Quantity
2
N=6096

3
N=293

X2 (P-value)

127 (57.2)
5912 (68.1)

12 (5.4)
278 (3.2)

12.58 (0.0019)

739 (31.7)
840 (28.7)
617 (26.7)
220 (28.4)

1447 (62.0)
2011 (68.7)
1665 (72.1)
548 (70.9)

146 (6.3)
75 (2.6)
28 (1.2)
5 (0.7)

150.64 (<.0001

3302
3341
2294

1012 (30.7)
970 (29.0)
602 (26.2)

2101 (63.6)
2306 (69.0)
1659 (72.3)

189 (5.7)
65 (2.0)
33 (1.5)

129.24 (<.0001

DIABETES
Yes
No

427
8561

141 (33.0)
2458 (28.7)

263 (61.6)
5833 (68.1)

23 (5.4)
270 (3.2)

11.40 (0.0034)

SLEEP QUALITY
Good
Moderate
Poor

2108
3365
3514

453 (21.5)
729 (21.7)
1417 (40.3)

1592 (75.5)
2545 (75.6)
1958 (55.7)

63 (3.0)
91 (2.7)
139 (4.0)

393.0 (<.0001)

Baseline Characteristics
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Table 12: Hazard Ratios for Sleep Quality and Quality as risk factors for Type-2 Diabetes
Sleep Quality
Good

Moderate

Poor

HR (95%CI)

HR (95%CI)

P-value

Baseline
Characteristics
Model 1

Referent

1.16 (0.89-1.52)

1.63 (1.26-2.10)

0.0001

Model 2

Referent

1.09 (0.83-1.43)

1.36 (1.04-1.76)

0.0356

Model 3

Referent

1.28 (0.95-1.72)

1.47 (1.09-1.99)

0.0392

Sleep Quantity (hours)
7-9

<7

>9

P-value

Model 1

Referent

1.26 (1.03-1.55)

1.93 (1.26-2.96)

0.0022

Model 2

Referent

1.25 (1.02-1.53)

1.56 (1.02-2.41)

0.0244

Model 3

Referent

1.06 (0.85-1.32)

1.46 (0.93-2.30)

0.2570

Model 1 was unadjusted. Model 2 was Age-adjusted. Model 3 was adjusted for Age, Sex, BMI, Race,
Hypertension, Cigarette Smoking, Alcohol Consumption, Depression, Coffee Drinking, Physical Activity,
and Education. The model 3 for sleep quality was adjusted for sleep quantity; likewise the model 3 for
sleep quantity was adjusted for sleep quality.
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Table 13: Effect of the interaction of BMI and Sleep Quality on Type-2 Diabetes

Normal BMI

HR (95% CI)
Good Sleep
(Referent)

HR (95% CI)
Moderate Sleep
4.70 (1.66-13.33)

HR (95% CI)
Poor Sleep
4.55 (1.61-12.90)

Overweight

8.97 (3.12-25.50)

8.28 (2.97-23.10)

8.74 (3.15-24.22)

Obese

19.88 (7.00-56.49)

23.32 (8.45-64.34)

31.11 (11.37-85.17)

Model adjusted for age, sex, race, hypertension, cigarette smoking, alcohol consumption,
depression, coffee consumption, physical activity, education, and sleep quantity.

Table 14: Effect of 1-unit change in sleep quality on type-2 diabetes within BMI classes
Normal BMI

Hazard Ratio
1.557

95% CI
1.107 – 2.191

Overweight

0.996

0.795 – 1.248

1.270
1.037 – 1.556
Obese
Model adjusted for age, sex, race, hypertension, cigarette smoking, alcohol consumption,
depression, coffee consumption, physical activity, education, and sleep quantity.
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CHAPTER FOUR

FACTORS AFFECTING TELOMERE LENGTH: THE ROLE OF OXIDATIVE
STRESS

4.1 INTRODUCTION
It has been established that telomere shortening decreases the proliferative
potential of the cells of the organism and causes aging of the organism. Aging has long
been known to be associated with decreased immune system function which implies that
shorter telomeres may be involved in compromising immune system function leading to
some of the late-life diseases in humans. Research has subsequently established that
telomere length is a biomarker of cumulative exposure to oxidative stress and a
prognostic indicator for risk of late-life diseases89, 171. Telomere shortening has been
associated with neurodegenerative diseases, infections, diabetes, malignancies,
autoimmune diseases, hypertension, atherosclerosis, cardiovascular disease, and mortality
especially from cardiovascular disease172-178. It is therefore of importance to public
health to identify factors associated with oxidative stress that contribute to telomere
length shortening with the aim that modifying these factors may reduce telomere attrition
and hence protect health. Factors such as obesity, physical inactivity, excessive use of
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alcohol, and use of tobacco products have been associated with increased oxidative stress
but research is limited on which of these factors actually contribute to telomere
shortening80, 81, 83, 84, 86, 88. This research is focused on identifying factors that influence
telomere length in order to contribute to available literature on telomere biology which is
important in improving human health.

4.1.1 Aim
This study investigates the effect of oxidative stress on telomere length in the
Framingham Heart Study (FHS). Factors associated with oxidative stress such as body
mass index, physical activity, tobacco use, and alcohol use will be investigated as to their
influence on telomere length.

4.1.2 Hypothesis
We hypothesize that factors that increase oxidative stress such as increasing BMI
(obesity), high tobacco and alcohol use, and physical inactivity will be associated with
shorter telomeres.

4.1.3 Justification
Telomere length shortening has been found in previous studies to be the
cumulative effect of oxidative stress and inflammation. Leucocyte telomere length
therefore is a dependable predictor of past metabolic history in biological organisms171.
Shorter telomeres have been linked to aging and age-related diseases and the search for
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ways to reduce telomere length shortening cannot be overemphasized. Identifying factors
that increase oxidative stress and therefore accelerate telomere length shortening is
important to ensuring good health.

4.2 METHODS
4.2.1 Study Design: Cross-sectional study of the association between telomere length
and body mass index, physical activity, tobacco use, and alcohol use.

4.2.2 Study Participants: This study enrolled subjects from the offspring cohort of the
Framingham Heart Study (FHS). The FHS is a health research project started in 1948
under the direction of the National Heart, Lung, and Blood Institute (NHLBI) with the
objective to identify the common factors that contribute to CVD. A total of 5,209 men
and women between the ages of 30 and 62 from the town of Framingham, Massachusetts,
were enrolled in the study. A second generation cohort made up of 5,124 offspring of the
participants of the original cohort was enrolled in 1971. The participants underwent
extensive physical examinations and lifestyle interviews at baseline, and followed up
every two years thereafter. The FHS is one of the most well-organized cohorts in
scientific research and has extensive information on major CVD risk factors such as high
blood pressure, smoking, obesity, diabetes, and physical inactivity. Studies based on the
FHS have contributed immensely to scientific literature over the last 50 years, and the use
of this cohort for our present research provides us with the advantage of quality medical
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and physical examinations, and laboratory tests, which are important in conducting valid
research179.

4.2.3 Inclusion Criteria
The offspring cohort was used for this study. The ages of the participants of the
offspring cohort at baseline ranged from 5 to 70 years (n=5,124). Participants without
history of any overt cardiovascular disease were included in this study. In addition, only
participants with telomere length records were included.
4.2.4 Exclusion Criteria
Participants whose telomere lengths could not be determined either due to
insufficient amount of DNA or poor DNA quality were excluded from this study (345 of
such exclusions were made in previous studies180, 181). A resultant sample of 974 subjects
was used for this study.

4.2.5 Measurement of Telomere Length
This study used leukocyte telomere length data of participants provided by FHS.
An independent laboratory that was blinded to all characteristics of the leukocyte donors
conducted the telomere length measurements by Southern blot analyses and the results
transmitted electronically to FHS only by ID numbers174, 180, 181.
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4.2.6 Assessment and Definition of Covariates
The FHS after obtaining informed consent, collected detailed physical and
medical information on all study participants. For this study, hypertension status was
defined according to the seventh report of the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) as either
“Normal”: systolic <120mmHg and diastolic <80mmHg; “Prehypertension”: systolic
120-139mmHg and diastolic 80-89mmHg; “Hypertension”: systolic ≥140mmHg and
diastolic ≥90mmHg. Body Mass Index (BMI) was calculated as weight (kg)/height (m)2
and categorized as normal (BMI <24.99), overweight (BMI 25-29.99), and obese (BMI
≥30). Self-reported smoking was coded as “never smoker”, “former smoker”, or “current
smoker”. Energy expenditure was used to assess physical activity and was used as
quartiles. Alcohol consumption was categorized as “nondrinker” “light”, “moderate”, or
“heavy” drinker based on number of drinks per week. The alcohol variable used in the
analyses was a combination of beer, red wine, white wine, and others including highballs
and cocktails. Light drinking comprised of taking 1-5 drinks per week, moderate drinking
was 6-13 drinks per week, and 14 or more drinks per week was categorized as heavy
drinking.

4.2.7 Statistical Analysis
Generalized linear models (GLM) were used to model the effect of physical
activity, body mass index, alcohol consumption, and tobacco use on telomere length.
Telomere length was normally distributed for this sample and did not call for any
transformation. Adjustments were made for age, gender, and hypertension to prevent
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confounding by these variables. All analyses were performed using SAS version 9.3.
Level of significance of all analyses was based on p-value of 0.05.

4.2.8 Power Calculation (factors affecting telomere length)
4.2.9 Prevalence of short telomeres among exposed and unexposed groups
For the purpose of estimating power for this study, telomere lengths were set at
median with “short” and “long” telomeres recorded as below and above median,
respectively. This implies 50% “short” telomere prevalence in the study sample.
4.2.10 Overweight/Obesity
More than 50% of U.S adults are overweight or obese182. Among the 974
Framingham cohort participants with telomere records, overweight or obese individuals
formed 69.9% resulting in exposed and unexposed samples of 681 and 293, respectively.
At 95% confidence level and 60% prevalence of short telomere among overweight or
obese participants, there is more than 80% power for this study [Table 15].
4.2.11 Cigarette Smoking
19.0% of all adults (aged 18 years or older), in the United States smoke
cigarettes183. Among the 974 Framingham cohort participants with telomere records, we
found 13.7% current smokers resulting in exposed and unexposed groups of 124 and 784
respectively. At 95% confidence level and 64% prevalence of short telomere among
Cigarette smoking participants, there is more than 80% power for this study [Table 15].
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4.2.12 Alcohol Use
Heavy drinking is defined as consuming more than 1 drink per day on average for
women and more than 2 drinks per day on average for men. 24% of men and 12% of
women binge drink. Binge drinking is defined as a pattern of alcohol consumption that
brings the blood alcohol concentration level to 0.08% or more which usually corresponds
to 5 or more drinks on a single occasion for men or 4 or more drinks on a single occasion
for women, within hours 184. In this study 33% of subjects consume 6 or more drinks per
week. Using 33% prevalence of excessive alcohol consumption for both males and
females and with a total of 974 Framingham cohort participants with telomere records,
the exposed and unexposed samples were 317 and 644 respectively. At 95% confidence
level and 59.9% prevalence of short telomere among excessive alcohol users, there is
more than 80% power for this study [Table 15].
4.2.13 Physical Inactivity
More than 50% of Americans do not meet the Physical Activity Guidelines for
aerobic physical activity185, and 25% of adults are completely inactive186. We categorized
physical activity into quartiles, and with the lowest quartile representing physically
inactive subjects, the exposed and unexposed samples will be 225 and 675 respectively.
At 95% confidence level and 61.1% prevalence of short telomere among physically
inactivity participants, there is more than 80% power for this study [Table 15].
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Table 15: Power Calculations (factors affecting telomere length)

Overweight/Obesity 681 (69.9%)

293

Prevalence
of short
telomere in
exposed
60%

Current smoking

124 (13.7%)

784

64%

50%

80.1%

Alcohol use

317 (33.0%)

644

59.9%

50%

80.7%

Physical Inactivity

225 (25.0%)

675

61.1%

50%

80.4%

Variable

Sample
Exposed

Sample
Unexposed
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Prevalence
of short
telomere in
unexposed
50%

Power
with
continuity
correction
80.6%

4.3 RESULTS
A total of 974 subjects were analyzed and the mean age was 58.2 years. Age
distributions for <50, 50-69, and >69 years were 15.3%, 72.5%, and 12.2%, respectively.
The mean BMI for the sample was 28.0 with overweight and obese subjects constituting
69.9%. Females formed 51.4%, and current smokers formed 13.7% of the sample.
Subjects who did not use alcohol formed 35.4% of the sample, and heavy drinkers (≥14
drinks/week) formed 13.0%. Subjects who were classified as hypertensive (≥140/90)
constituted 40.8% of the sample [Table 16]. Telomere length was normally distributed
with a mean of 6.99kbp (6.99 kilo base-pairs). Unadjusted analyses have shown that
increasing age, BMI, male gender, and hypertension were significantly associated with
telomere length shortening, while cigarette smoking, energy expenditure, and alcohol
consumption were not.
In the multivariable model age, gender, BMI, and alcohol consumption were
significantly associated with telomere length [Table 17]. Hypertension and energy
expenditure were not found to influence telomere length or confound the association
between telomere length and the other variables in the model and were eliminated from
further analyses. Cigarette smoking although not significantly associated with telomere
length in both the unadjusted and multivariable models, it has been found to confound the
association between alcohol use and telomere length in the multivariable model [Table
18]. The effect estimate between alcohol use and telomere length was attenuated by the
presence of cigarette smoking in the model making alcohol use not quite statistically
significant (p=0.0983) [Table 18]. Age, gender, and BMI were still significantly
associated with telomere length when cigarette smoking was added to the model. A unit
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increase in age was associated with 21.1bp (21.1 base-pairs) decrease in telomere length
(p <.0001) [Table 18]. Compared to subjects below 50 years old, subjects 70 years or
older have 596bp shorter telomeres (p <.0001) [Table 19]. A unit increase in BMI was
associated with 8.5bp decrease in telomere length (p=0.0164) [Table 18]. Overweight
subjects have 73.8bp shorter telomeres compared to normal weight subjects but was
nonsignificant (p=0.1024), and obese subjects have 113bp shorter telomeres compared to
normal weight subjects (p=0.0193) [Table 19]. There was no difference between nondrinkers and light drinkers (1-5 drinks/per week). The non-drinker and light drinker
classes have therefore been collapsed for comparison with moderate and heavy drinking
classes. Moderate drinking was associated 18.2 bp shorter telomere length compared to
the none or light drinker group but the association was nonsignificant (p=0.6999), and
heavy drinking was associated with 93.1bp shorter telomeres compared to the none or
light drinker group (p=0.0976) [Table 19].
Males were significantly more likely to have shorter telomeres (108.5bp shorter)
compared to females (p=.0041) [Table 18]. This estimate was attenuated by about 5bp
but remained significant (p=0.0073) when categories of the other variables were
considered instead of interval [Table 19]. Current smoking was associated with 69.2bp
shorter telomeres compared to no smoking but the association did not reach statistical
significance (p=0.2551).
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4.4 DISCUSSION
The results of the study have shown that age, gender, and BMI have significant
influence on telomere length. The association between aging and telomere attrition has
long been established. Telomeres shorten at every cell division and one would expect
that when all other factors are held constant older people should have shorter telomeres
compared to younger people. During the formation of peripheral leucocytes there is
successive division of hematopoietic stem cells and progenitor cells contributing to the
telomere shortening with age. In this sample, comparing subjects above 50 years old to
subjects less than 50 years have shown that telomeres shorten at a rate of approximately
200bp for every 10 years after the age 50. Telomere length therefore has been proposed
by some researchers to be an indicator of biological age187. Cell division is necessary for
growth but does not tell the whole story about the shortening of telomeres with age.
Hence characterizing telomere length as a biological age indicator has been argued
against by other researchers188. Other proposals put forth to explain the shortening of
telomeres with age include inflammation and oxidative stress174, 175, 189. Inflammation
increases the demand for cell replication and hence accelerated shortening of telomeres.
The number of telomere repeats lost per cell replication has also been found to increase
due to oxidative stress190-192. Inflammation and oxidative stress play important roles in
aging and late-life diseases23, 193 and their association with telomere shortening explains
the increased incidence and prevalence of late-life diseases, particularly cardiovascular
disease among individuals with shorter telomeres175, 178, 194, 195. The rate of telomere
shortening with age was investigated by Vaziri et al.,196 among 140 individuals (0-107
years old) including 21 Down syndrome (DS) patients. They found that among 119
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unrelated normal individuals, mean telomere length of peripheral blood T lymphocytes
declined at a rate of 41 bp per year (P < .00005; r = .83). They also found that the rate of
loss in DS patients was threefold higher than in age-matched normal individuals (rate of
among DS patients: 133 ± 15 bp/year; rate of loss among age-matched normal
individuals: 43 ± 7.7 bp/year; P < .0005). Down syndrome is characterized by immune
function loss which implies that accelerated loss of peripheral blood T lymphocytes could
be a reflection of immune cell senescence in DS patients. In our study, the rate of
telomere attrition was 21 bp per year after adjusting for gender, body mass index, alcohol
use, and cigarette smoking [Table 18]. These adjustments could be a source for the
differences in estimates between our study and that of Vaziri et al. Moreover, Vaziri et
al., were more specific, that is, they measured T lymphocytes rather than a broad category
of leucocytes. Furthermore, our analyses involved over 900 subjects whilst results by
Vaziri et al., were based on 140 individuals including 21 DS patients.
Our analyses also showed a significant difference in telomere length between
males and females (Males vs. females: β=-103 bp, p=0.0073) [Table 19]. This result also
conforms to published literature about telomere length differences by gender196, 197. In
the study by Vaziri et al., males have a faster rate of loss in telomeric DNA compared to
females although the difference was not significant (50 ± 4.2 vs. 40 ± 3.6 bp/year, P = .1).
Bekaert at al.,198 in their investigation into the association between telomere length and
CVD risk factors also showed that females have significantly longer telomeres compared
to males. Meta-analyses by Gardner et al.,197 from 36 cohorts (36,230 participants)
provided further evidence that females on average have longer telomeres compared to
males. There are many schools of thought concerning the gender difference between
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males and females. The study by Aubert et al.,199 found that females have longer
telomeres at birth compared to males, but the difference was not statistically significant.
Okuda et al.,200 found no evidence of telomere length difference by gender at birth, and
suggested that longer telomeres in females than males that occur in adulthood could be
due to slower rate of telomere attrition in females. Slower rate of telomere attrition in
females could mean reduced oxidative stress because in telomere biology, the influence
of free radicals is a major component of telomere attrition89. In support of this it has been
found that females produce fewer reactive oxygen species than men. This is possible
through the many actions of estrogen in scavenging free radicals, or inhibiting their
formation, and ability to stimulate enzymes to detoxify free radicals201. Thus, the
antioxidant properties of estrogen serve to preserve telomeres of females or at least slow
the rate of attrition. It is also thought that estrogen might stimulate telomerase to add
telomere repeats to the ends of chromosomes given that an estrogen-response element is
present in the telomerase reverse transcriptase201. Estrogen has also been found to
stimulate nitric oxide production in vascular endothelial cells, which leads to stimulation
of telomerase in these cells and could protect against endothelial dysfunction that
characterize oxidative stress202.
Obesity is another important factor in telomere biology. It is currently a global
epidemic and has been implicated in many disease processes. Obesity is characterized by
a state of high-systematic oxidative stress and inflammation203 and because telomeres are
very vulnerable to attack by reactive oxygen species204, it has been postulated that
telomere attrition could be accelerated by obesity. We found in our analysis that a unit
increase in BMI is associated with 8.5 bp (0.0085 kbp) decrease in telomere length
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(p=0.0164) [Table 18]. When obese subjects (BMI ≥30) were compared with normal
subjects (BMI<25), it was found that obesity is associated with 113 bp shorter telomeres
(p=0.0193) [Table 19]. The study by Fitzpatrick et al.,175 in the Cardiovascular Health
Study showed similar results when they compared overweight subjects with normal
subjects (β=-117 bp, p=0.06). Their overweight class however included obese subjects.
Our sample size was more than twice theirs (419) and may be the reason for their p-value
of 0.06. Lee et al.,205 also showed that BMI was inversely associated with telomere length
although they used the ratio of telomere repeat copy number (T) and single-copy gene
copy number (S),T/S ratio, to estimate telomere length whiles we used terminal
restriction fragments (TRF) method.
The study by Diaz et al.,206 involving 317 subjects between the ages of 40 and 64
did not show any association between BMI and telomere length. Our sample of 974 is 3
times bigger and could be among reasons for the varying results. A recent meta-analysis
by Müezzinler et al., gave credence to our results. They found that a unit increase in BMI
is associated with 8.0 bp (0.008 kbp) decrease in telomere length (p=0.058). Although
their p-value was only marginally statistically significant, we got approximately the same
estimate for the effect of BMI on telomere length and this is worth noting. Obesity begins
with high caloric intake and less physical activity. The result is accumulation of excess
fat in the adipose tissue, leading to low-grade inflammation, hypoxia and increased free
radical production207, 208. This alters the secretion of adipokines (adiponectin and leptin)
and cytokines (TNFα, IL-1β, and IL-6), by the adipose tissue. This then manifests as
health problems particularly, insulin resistance, diabetes, and atherosclerosis. Obesity
therefore, is associated with hyperglycemia, high levels of circulating free fatty acids,
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decreased antioxidant defenses and chronic inflammation. The resultant enhanced
oxidative stress could explain the association between obesity and telomere attrition.
Alcohol consumption and cigarette smoking were not found to significantly
influence telomere length in our study. Alcohol use was marginally associated with
telomere length when smoking was not considered [Table 17] but after adjustment for
cigarette smoking the effect was no longer significant [Table 18]. A study of business
men in Helsinki209 found that compared with non-drinkers, subjects who drank more than
one drink per day have significantly shorter telomeres. One drink per day was not found
to be significantly associated with telomere length and conforms to the protection offered
by light to moderate drinking as found by some studies. In this study, light drinkers and
non-drinkers were combined because they these groups were not different in their effects
on telomere length. In another study involving Caucasian males living in Northeastern
Italy, it was found that alcohol abusers have significantly shorter telomeres (almost
halved) compared to controls. The association was also found in their linear model with
decreasing telomere lengths associated with increasing amount of drinks per day210. In
Japan, specimens of the esophagus were collected from 26 alcoholic patients with mean
age of 61.2 years, and compared with specimens of normal esophageal mucosa obtained
from 24 autopsy cases with mean age of 73.3 years. When telomeres in the basal cells of
the esophageal epithelium were measured it was found that those from the alcoholics
were significantly shorter than the normal controls211. This study focused on telomere
length from the esophageal mucosa whilst we measured leucocyte telomere length.
Nevertheless, both studies are comparable in terms of highlighting the harmful effects of
excessive alcohol consumption. It has been suggested that some alcohol use may be
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beneficial and the study by Sun et al.,84 has provided evidence. They analyzed 5,862
women in the Nurses’ Health Study and found that moderate drinking (1 drink/week to 2
drinks/day), was associated with longer telomere length although the association was not
statistically significant. They further put together all low-risk factors such as non-current
smoking, maintaining a healthy body weight, engaging in regular moderate or vigorous
physical activities, drinking alcohol in moderation, and eating a healthy diet, and found
that the higher the number of low-risk factors, the longer the telomeres (p= 0.015). Light
to moderate drinking has also been found to reduce cardiovascular risk in a meta-analysis
involving 84 studies. The pooled adjusted relative risk for CVD mortality was 0.75 (0.70
to 0.80) for alcohol drinkers compared to non-drinkers. For coronary heart disease
mortality, it was found that 1-2 drinks a day provided the lowest risk and for stroke
mortality the lowest risk was found for drinking ≤1 drink per day212. Another metaanalysis involving 23 studies has also found that moderate alcohol intake is protective
against dementia and Alzheimer's disease213. A prospective study of U.S. adults aged 55
and older in the Health and Retirement Study found that moderate drinking (1 drink/d)
was strongly associated with less mortality and better risk factor profiles, compared to no
drinking214. With all the proposed benefits of light to moderate alcohol use, the
mechanisms influencing telomere shortening are not clearly defined. As outlined earlier,
telomeres are vulnerable to oxidative stress and it is plausible that alcohol-induced
increase in oxidative stress, inflammation, and impaired antioxidant systems are the main
mechanisms linking excessive alcohol use to telomere attrition.
Cigarette smoking has been linked with telomere shortening although we did not
find a significant association. Valdes et al.,81 found a dose-response relationship between
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smoking and telomere length where each pack-year of cigarette smoked was equivalent to
an additional 5 bp of telomere length lost compared with the rate in the overall cohort
(p=0.017). Our study categorized smoking as “never”, “former”, and “current” rather
than pack years and our analysis comprised of males and females together whiles Valdes
et al., studied only women. In a cross-sectional study of 20 current smokers and 20 nonsmokers, a higher mean pack year of cigarette was found in subjects with negative
telomerase reverse transcriptase (hTERT) expression in the skin (P < 0.01)215.
Telomerase is a ribonucleoprotein polymerase that maintains telomere ends by adding the
telomere repeat “TTAGGG”. The telomerase reverse transcriptase (hTERT) is a catalytic
subunit of the enzyme telomerase. Hence negative action of smoking on hTERT
expression implies shorter telomeres. Active smoking was found in the Prevention of
Renal and Vascular End-stage Disease (PREVEND) study, to almost triple the rate of
telomere attrition per year (P < 0.0001)216. It is biologically plausible that smoking is
associated with telomere length which could translate into health related states linked to
both smoking and shortened telomeres. Cigarette smokers are at higher risk of developing
several chronic disorders including buildups in arteries, some types of cancer, and
chronic obstructive pulmonary disease. It has been estimated that 30% of all cancer
deaths, 20% of all coronary heart diseases and strokes, and 80% of all chronic obstructive
pulmonary disease are attributable to cigarette smoking. Smoking has been found to be
the main contributor to lung cancer, atherosclerosis, and myocardial infarctions217-219.
Smoking could induce oxidative stress and accelerate telomere attrition because cigarette
smoke contains a large variety of compounds, including oxidants and free radicals that
are capable of initiating and promoting oxidative damage to tissue proteins.
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It has been shown in this research that age, gender, and BMI have significant
effects on telomere length. The associations were strong and conform to existing
literature on the association between these factors and telomere length. The Framingham
Heart Study (FHS) from which we performed these analyses is known for high data
quality which reflects on the validity of our study. Our study however is not devoid of
limitations. Firstly, we performed a cross-sectional analysis to study the associations
presented. Prospective studies are better because they can establish temporality, but
telomere shortening, according to the biology occurs with age and highly influenced by
stress from oxidation. Hence although we conducted a cross-sectional study, we have no
reason to suspect the direction and validity of our estimates. Secondly, the sample
involved mainly Caucasian (99%) and results may not apply to other race/ethnicities.
Thirdly, a much larger sample than we used (974) could be helpful in bringing out certain
unseen effects and make the results more reliable. However, our results were comparable
to those from other studies with even much smaller sample size. Fourthly, the effect of
alcohol on telomere length could be even clearer if had analyzed each alcoholic beverage
separately. We analyzed all alcoholic beverages together because of very low numbers
reported per alcohol type. Our results were however comparable to other studies which
used the same approach. It is important that future studies have samples large enough to
increase reliability of results and also take advantage of the useful information to be
gained by analyzing each alcohol type separately.
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4.5 CONCLUSION
Telomeres consist of nucleotide repeats that cap the ends of chromosomes and are
essential to maintaining chromosomal integrity. Telomere shortening has been implicated
in disease including Down syndrome, Alzheimer’s disease, some cancers, coronary heart
disease, stroke, myocardial infarctions, and atherosclerosis. Healthy lifestyle factors such
as non-current smoking, maintaining a healthy body weight, engaging in regular
moderate or vigorous physical activities, drinking alcohol in moderation, and eating a
healthy diet have been found to reduce telomere attrition. The opposite of these promote
increased oxidative stress and inflammation, which enhances white blood cell turnover
resulting in increased rate of telomere erosion per cell division. Although age and gender
have strong effects on telomere length as seen in this analysis, they are not modifiable.
However the rate of attrition can be reduced by lifestyle choices that will minimize the
oxidative burden on telomeres. In light of these results, a lot needs to be done in
educating the public to take seriously those activities that lower the risk of telomere loss
and promote a healthy life.
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Table 16: Characteristics of Study Participants by Leucocyte Telomere length

VARIABLE

N

Leucocyte Telomere Length (kbp)
Quartile 1 Quartile 2 Quartile 3
N=243
N=244
N=243

BMI (mean, s.d)
AGE (mean, s.d)

974
973

28.6 (5.4)
61.4 (8.7)

28.0 (5.2)
59.3 (8.7)

27.5 (4.7)
57.9 (8.2)

Quartile 4
N=244

F (P-value)

27.7 (5.5)
54.1 (8.0)

4.88 (0.0274)
94.25 (<.0001)
X2 (P-value)

BMI
Normal
Overweight
Obese

293
399
282

63 (21.5)
98 (24.6)
82 (29.1)

67 (22.9)
107 (26.8)
70 (24.8)

74 (25.3)
105 (26.3)
64 (22.7)

89 (30.4)
89 (22.3)
66 (23.4)

AGE
<50
50-59
60-69
≥70

149
429
276
119

20 (13.4)
84 (19.6)
88 (31.9)
51(42.9)

29 (19.5)
100 (23.3)
81 (29.4)
34 (28.6)

30 (20.1)
121 (28.2)
71 (25.7)
21 (17.7)

70 (47.0)
124 (28.9)
36 (13.0)
13 (10.9)

100.96(<.0001)

SEX
Male
Female

473
500

135 (28.5)
108 (21.6)

130 (27.5)
114 (22.8)

111 (23.5)
132 (26.4)

97 (20.5)
146 (29.2)

15.01 (0.0018)

BLOOD PRESSURE
Normal
Prehypertension
Hypertension

276
301
397

50 (18.1)
77 (25.6)
116 (29.2)

68 (24.6)
71 (23.6)
105 (26.4)

70 (25.4)
79 (26.2)
94 (23.7)

88 (31.9)
74 (24.6)
82 (20.7)

17.41 (0.0079)

CIGARETTE
Non-smoker
Former smoker
Current smoker

270
514
124

69 (25.6)
130 (25.3)
32 (25.8)

64 (23.7)
131 (25.5)
33 (26.6)

67 (24.8)
124 (24.1)
32 (25.8)

70 (25.9)
129 (25.1)
27 (21.8)

1.10 (0.9815)

ENERGY
1st Quartile
EXPENDITURE
2nd Quartile
3rd Quartile
4th Quartile

225
225
225
225

59 (26.2)
54 (24.0)
59 (26.2)
51(22.7)

53 (23.6)
55 (24.4)
61 (27.1)
56 (24.9)

58 (25.8)
60 (26.7)
49 (21.8)
61 (27.1)

55 (24.4)
56 (24.9)
56 (24.9)
57 (25.3)

3.07 (0.9614)

ALCOHOL
None
1-5 Drinks/week
6-13 Drinks/week
≥14 Drinks/week

340
304
192
125

94 (27.7)
66 (21.7)
49 (25.5)
34 (27.2)

78 (22.9)
73 (24.0)
50 (26.0)
37 (29.6)

84 (24.7)
75 (24.7)
48 (25.0)
33 (26.4)

84 (24.7)
90 (29.6)
45 (23.5)
21 (16.8)

10.57 (0.3061)

BEER
None
1 Drink/week
2-4 Drinks/week
≥5 Drinks/week

675
94
103
97

177 (26.2)
18 (19.2)
24 (23.3)
24 (24.7)

160 (23.7)
26 (27.7)
23 (22.3)
32 (33.0)

164 (24.3)
23 (24.5)
35 (34.0)
20 (20.6)

174 (25.8)
27 (28.7)
21 (20.4)
21 (21.7)

11.51 (0.2424)
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10.11 (0.1200)

Table 16: Characteristics of Study Participants by Leucocyte Telomere length (continued)
VARIABLE
RED WINE
None
1 Drink/week
2-4 Drinks/week
≥5 Drinks/week
WHITE WINE
None
1 Drink/week
2-4 Drinks/week
≥5 Drinks/week

N

Leucocyte Telomere Length (kbp)
Quartile 1 Quartile 2
Quartile 3
N=243
N=244
N=243

Quartile 4
N=244

X2 (P-value)

720
102
85
65

184 (25.6)
21 (20.6)
20 (23.5)
18 (27.7)

176 (24.4)
28 (27.5)
23 (27.1)
17 (26.2)

176 (24.4)
26 (25.5)
24 (28.2)
16 (24.6)

184 (25.6)
27 (26.5)
18 (21.2)
14 (21.5)

3.09 (0.9605)

658
127
118
67

173 (26.3)
27 (21.3)
27 (22.9)
16 (23.9)

164 (24.9)
38 (29.9)
26 (22.0)
15 (22.4)

159 (24.2)
31 (24.4)
31 (26.3)
21 (31.3)

162 (24.6)
31 (24.4)
34 (28.8)
15 (22.4)

5.50 (0.7887)

OTHERS
None
690 174 (25.2)
165 (23.9)
176 (25.5)
175 (25.4)
1 Drink/week
105 20 (19.0)
28 (26.7)
22 (21.0)
35 (33.3)
2-4 Drinks/week
88
22 (25.0)
28 (31.8)
23 (26.1)
15 (17.1)
≥5 Drinks/week
83
27 (32.5)
20 (24.1)
19 (22.9)
17 (20.5)
12.26 (0.1992)
Leucocyte Telomere Length: Quartile 1 (<6.560); Quartile 2 (6.560- 6.953); Quartile 3 (6.954- 7.387);
Quartile 4 (>7.387).
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Table 17: Regression estimates of the factors affecting telomere length
Parameter
Age

Estimate
-0.0211

Standard
Error
0.0020

t Value
-10.61

Pr >|t|
<.0001

Sex (M)

-0.1167

0.0361

-3.24

0.0012

BMI

-0.0080

0.0034

-2.38

0.0176

Alcohol use

-0.0047

0.0024

-2.00

0.0454

Table 18: Regression estimates of the factors affecting telomere length
Parameter
Age

Estimate
-0.0211

Standard Error
0.0021

t Value
-10.08

Pr >|t|
<.0001

Sex (M)

-0.1085

0.0377

-2.88

0.0041

BMI

-0.0085

0.0035

-2.40

0.0164

Alcohol use
Smoking
Non-smoker

-0.0040

0.0024

-1.65

0.0983

Referent

Former smoker

0.0162

0.0416

0.39

0.6969

Current smoker

-0.0669

0.0603

-1.11

0.2672
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Table 19: Estimates of the factors affecting telomere length (variables as categories)
Parameter
AGE
<50
50-59
60-69
≥70

N

Estimate

Standard
Error

t Value

Pr >|t|

149
429
276
119

Referent
-0.200
-0.425
-0.596

0.055
0.059
0.070

-3.67
-7.24
-8.44

0.0003
<.0001
<.0001

SEX
Male
Female

473
500

-0.103
Referent

0.038

-2.69

0.0073

BMI
Normal
Overweight
Obese

293
399
282

Referent
-0.074
-0.113

0.045
0.048

-1.64
-2.34

0.102
0.019

ALCOHOL
0-5 Drinks/week
6-13 Drinks/week
≥14 Drinks/week

644
192
125

Referent
-0.018
-0.093

0.047
0.056

-0.39
-1.66

0.700
0.098

Smoking
Non-smoker
Former smoker
Current smoker

270
514
124

0.009
-0.069

0.042
0.061

0.22
-1.14

0.826
0.255
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CHAPTER FIVE

SUMMARY AND CONCLUSION
5.1 Oxidative Stress
All aerobic organisms require oxygen for survival. During metabolism oxygen is
used to produce ATP and water. The mitochondrion is the site of metabolism and
dysfunction results in impairment of the electron transport chain producing conducive
environment for reactive oxygen species. Reactive oxygen species include superoxide
(O2•-), hydrogen peroxide (H2O2), hydroxyl radical (OH•), hydroxyl ion (OH-), and nitric
oxide (NO•). Reactive oxygen species can be produced at other sites by different
enzymes, apart from the mitochondria. These include NADPH oxidase at the plasma
membrane, lipid oxidation within peroxisomes, and xanthine oxidase in the cytoplasm.
Living cells are equipped with defense mechanisms to lessen the harmful effects
of reactive oxygen species. Superoxide dismutase (SOD) catalyzes the conversion of
superoxide anions into hydrogen peroxide and oxygen. In the peroxisomes of eukaryotic
cells, the enzyme catalase converts hydrogen peroxide to water and oxygen, completing
the detoxification that was started by SOD. Catalase is more active when levels of
hydrogen peroxide are low. Another group of enzymes called glutathione peroxidase
catalyze the detoxification of hydrogen peroxides when present at high concentrations.
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The proper functioning of these antioxidant enzymes depends on the availability of
micro-nutrients such as iron, copper, zinc, and selenium. Dietary antioxidants including
vitamins E, C, and D, flavonoids and carotenoids are also known to reduce or inhibit
formation of reactive oxygen species. Accelerated reactive oxygen species production
occurs when micro-nutrients that are important for antioxidant enzyme function, and
dietary antioxidants are exhausted. This imbalance between the cell’s defense systems
and reactive oxygen species is known as oxidative stress.
Oxidative stress causes oxidative damage resulting in cell injury. Oxidative
damage to DNA can cause DNA mutation leading to changes in protein gene expression.
Protein modifications caused by reactive oxygen species have been found in elevated
levels in diseased tissues in patients with inflammatory diseases. Lipids also undergo
peroxidation in the presence of reactive oxygen species. Lipid peroxidation initiates the
formation of plaques in the arteries with time giving rise to atherosclerosis. Lipid
peroxidation is one of the most widely used indicators of oxidative stress. Oxidative
stress has been implication in diabetes, Parkinson’s disease, Alzheimer’s disease,
amyotrophic lateral sclerosis, Huntington disease, cancer, and cardiovascular disease.
Lifestyle factors such as overweight and obesity, cigarette smoking, excessive
alcohol consumption, and inactivity have been associated with increased oxidative stress.
Obesity is accumulation of excess fat in the adipose tissue resulting in alteration in
secretion of adipokines and cytokines. Obesity is characterized by high levels of
circulating free fatty acids, decreased antioxidant defenses and chronic inflammation and
hence enhanced oxidative stress. Cigarette smoke contains a large variety of compounds,
including oxidants and free radicals, and alcohol could induce inflammation impair
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antioxidant systems. Physical activity is important in utilizing ATP and prevents the
harboring of electrons in the electron transport chain. Inactivity therefore promotes the
harboring of excess electrons in the transport chains leading to reactive oxygen species
production and hence oxidative stress.

5.2 Sleep Disordered Breathing
Sleep-Disordered breathing (SDB) describes a group of disorders characterized by
inadequate ventilation or abnormal breathing during sleep. It involves total or partial
collapse of the pharyngeal airway during sleep necessitating arousal to resume
ventilation. The intermittent hypoxia followed by reoxygenation has been associated with
reactive oxygen species production. Several studies have also shown that plasma levels of
lipid peroxidation biomarkers such as thiobarbituric reactive substances (TBARS) and
peroxides (PD) were significantly higher among sleep apnea patients than normal
controls. Since lipid peroxidation plays a key role in the formation of atherosclerosis
plaques, SDB patients have been found to be at greater risk of atherosclerosis and
mortality from cardiovascular diseases. This study investigated the association between
SDB and CML concentration and found that participants with SDB have higher CML
levels than participants without SDB, within certain hemoglobin ranges. High CML
concentration is an indication of oxidative stress. Some participants with SDB have been
found to have lower CML concentration which has been attributed to their physical
fitness because moderate to high physical activity has been associated with reduced
oxidative stress. It should also be noted that we studied an older population (mean age
77.5 years) and most males with severe SDB may have died before CML was measured.
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The lower CML values found among males who have survived may not be a protective
effect of severe SDB but may be due other reasons not assessed in this study. CML
values from a younger population may be important in understanding the relationship
between SDB and CML concentration. Part of this dissertation also looked at sleep
disturbances and type-2-diabetes. As described above sleep disturbances have oxidative
stress consequences. The β-cells of the pancreas lack catalase and are vulnerable to the
toxic effects mediated by reactive oxygen species. Findings from this study indicated
higher risk of type-2-diabetes among subjects with poor sleep quality which was further
exacerbated by obesity. Hence taken together, these observations emphasize the
importance of SDB in oxidative stress and its consequences.

5.3 Carboxymethyl-lysine (CML)
Advanced glycation end-products (AGEs) are a heterogeneous group of
macromolecules that are formed by the non-enzymatic glycation of proteins, lipids, and
nucleic acids. CML is a dominant AGE and is formed on protein by combined nonenzymatic glycation and oxidation (glycoxidation) reactions. It is also formed during
lipid peroxidation (metal-catalyzed oxidation of polyunsaturated fatty acids in the
presence of protein. Lipids undergo peroxidation in the presence of reactive oxygen
species. Hence Lipid peroxidation is one of the most widely used indicators of oxidative
stress. Since CML is formed from lipid peroxidation, it has been characterized as the
general biomarker of oxidative stress. CML has therefore been associated with many of
the disorders known to be related to oxidative stress including Parkinson’s disease,
Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington disease, rheumatoid
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arthritis, end-stage renal disease, hypertension, atherosclerosis, and cardiovascular
disease. The importance of studying the association between CML and SDB is to
establish grounds for preventive measures. SDB treatment by use of CPAP has been
successful hence in order to reduce CML concentration and prevent disease, treatment of
sleep problems could be considered among the many strategies.

5.4 Telomeres
Telomere attrition has been implicated in diseases including cancer, diabetes,
hypertension, atherosclerosis, coronary artery disease, and chronic heart failure.
Telomeres shorten at each cell division until a threshold is reached where no further
replication can take place (cellular senescence). Telomere length therefore depends on
age but shortening can be accelerated by oxidative stress. Oxidative stress and
inflammation enhances white blood cell turnover resulting in increased rate of telomere
erosion per cell division. Lifestyle factors such as current smoking, overweight and
obesity, sedentary lifestyle, excessive alcohol consumption, and unhealthy diet have been
found to increase telomere attrition. Public health messages directed towards these
lifestyle factors may go a long way to promote good health and longevity.

5.5 Aging and Age-related Diseases
Since proposed by Harman in 1956, the free radical theory remained the most
popular theory of aging and age-related diseases. As mentioned above, oxidative stress
contributes to telomere shortening and therefore places limit on the replicative potential
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of the cell. Loss of replicative potential leads to cellular senescence. CML concentrations
were also higher with increased oxidative stress. According to Harman the accumulation
of the impact of oxidative stress on cells over time contribute to the aging of the
organism. Both high CML concentration and shortened telomeres are very dependent on
age and are associated with degenerative diseases. Since the mitochondria produces most
of the reactive oxygen species, is has been proposed that the higher the metabolic rate of
an organism the greater the production of reactive oxygen species and hence the shorter
the life span of the organism. In response to this hypothesis, a strategy like caloric
restriction has been proposed as a way to reduce oxidative damage and disease. As shown
in this study, sleep hygiene is something to consider in the policy framework of
interventions aimed at aging and degenerative diseases. Other healthy lifestyle factors to
consider include maintaining a healthy weight, smoking cessation, moderation in alcohol
consumption, and moderate to high physical activity.

5.6 Recommendations for Future Research
The biology of oxidative stress and health have been received a lot of attention
since the 1950s yet there is still much to be known on the topic. Inflammation and
oxidative stress factors have been associated with telomere length in this study and
oxidative stress from sleep disordered breathing has been associated with CML
concentration. Telomere shortening and CML concentration have been implicated in
degenerative diseases but the association between them is yet to be studied. Future
studies may investigate this association to determine if shorter telomeres are associated
with high CML concentrations or vice-versa. Further studies are also needed to verify if
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higher CML concentration as a result of SDB is actually associated with a disease
outcome in the CHS. Furthermore, the association between hemoglobin, SDB, and CML
needs to be replicated with a much larger sample and if possible longitudinally.
Specifically, a future study could focus on investigating the protective effect of SDB on
CML concentration among males with high hemoglobin.
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